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Marine environments are largely unexplored and can be a source of new molecules for
the treatment of many diseases such as malaria, cancer, tuberculosis, HIV etc. The
Marine environment is one of the untapped bioresource of getting pharmacologically
active nonribosomal peptides (NRPs). Bioprospecting of marine microbes have achieved
many remarkable milestones in pharmaceutics. Till date, more than 50% of drugs which
are in clinical use belong to the nonribosomal peptide or mixed polyketide-nonribosomal
peptide families of natural products isolated from marine bacteria, cyanobacteria and
fungi. In recent years large numbers of nonribosomal have been discovered from marine
microbes using multi-disciplinary approaches. The present review covers the NRPs
discovered from marine microbes and their pharmacological potential along with role of
genomics, proteomics and bioinformatics in discovery and development of nonribosomal
peptides drugs.
Keywords: microbe derived-compounds, marine natural products, nonribosomal peptides, antimicrobial,
anticancer
MARINE ECOSYSTEM RESOURCES FOR NEW DRUG
DISCOVERY
The marine ecosystem is most complex and largest aquatic systems on earth. It includes
oceans, intertidal ecology, salt marsh, lagoons, estuaries, coral reefs, mangroves, deep sea,
sea floor etc. Marine ecosystem has a enormous variety of organisms that are different
in their physiology and adaptations and most of the marine life is found in coastal
habitats (Hedgepeth, 1957). According to the Global Biodiversity Assessment by the United
Nations Environment Program, oceans consist of 178,000 marine species in 34 phyla. It is
estimated that 102 fungi, 103 bacteria and 107 viruses are likely to exist in one milliliter
of seawater (Kubanek et al., 2003). Marine organisms comprise around 50% of the total
biodiversity on earth. These organisms have shown remarkable contribution in the discovery
and production of novel biomolecules (Jimeno et al., 2004; Vignesh et al., 2011). During 1981–
2002 50% of US- FDA approved drugs are reported from either marine bioactive compounds
or their synthetics analogs (Vinothkumar and Parameswaran, 2013). Cytosine arabinoside,
Ara-C (anticancer) and adenine arabinoside, Ara-A (antiviral) were first discovered in the
early 1950s and approved by Food and Drug Administration (US-FDA). These drugs were
isolated from Caribbean sponge (Cryptotheca crypta), as spongouridine and spongothymidine.
Blunt et al. (2015) reported more than 20,000 natural bioactive compounds have been
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obtained from marine environment in last 50 years (Blunt et al.,
2015). Out of these 9 were approved as drugs and many of them
are still in clinical trials. It is well documented thatmore than 50%
of drugs that are in clinical use today belong to the nonribosomal
peptides or mixed polyketide-NRP families (Hranueli et al.,
2010; Agrawal et al., 2016; Table 1). Marine microbes contributes
70% of discovery of NRPs with antimicrobial, antiviral,
cytostatic, immunosuppressant, antimalarial, antiparasitic,
animal growth promoters and natural insecticides activities
etc. (Vinothkumar and Parameswaran, 2013). Which makes
marine microbial an important bioresource for getting NRPs
with numerous pharmaceutical applications. The examples
of some NPR based drugs which are now in the market are
Daptomycin (antibiotics), Bleomycin (antitumor), Bacitracin
(antibiotics for skin infections), Cyclosporin (antifungal and
immunosuppressant drugs) (Figure 1) (Strieker et al., 2010).
Norine is the first database entirely dedicated to NRPs and
contains more than 1186 entries (Caboche et al., 2008, 2009).
In this review we focus on antimicrobial and anticancer NRPs
reported from marine microbes with their biological targets.
NONRIBOSOMAL PEPTIDE AND THEIR
BIO COMBINATORIAL SYNTHESIS
An extensive literature on biosynthesis of non-ribosomal
peptides is available in previous reviews (Sieber and Marahiel,
2003; Finking and Marahiel, 2004; Caboche et al., 2009; Strieker
et al., 2010; Pfennig and Stubbs, 2012). Here we just summarized
how NPRs are synthesized biologically, biomolecular structural
architecture and enzymatic machinery of non-ribosomal peptide
synthetases (NRPSs). NRPs are peptide secondary bioactive
metabolites synthesized by a multi-modular enzyme complex
called nonribosomal peptide synthetases (NRPSs) found only in
bacteria, cyanobacteria and fungi (Matsunaga and Fusetani, 2003;
Nikolouli and Mossialos, 2012). NRPs are formed from a series
of enzymatic transformations employing a much more diverse
set of precursors and biosynthetic reactions. NRPSs utilize both
proteinogenic and nonproteinogenic amino acids (not encoded
by DNA) as building blocks for the growing peptide chain
(Finking and Marahiel, 2004; Felnagle et al., 2008). Moreover,
these secondary bioactive metabolite peptides contain unique
structural features, such as D-amino acids, N-terminally attached
fatty acid chains, N- and C-methylated residues, N- formylated
residues, heterocyclic elements, and glycosylated amino acids, as
well as phosphorylated residues etc.; (Sieber andMarahiel, 2003).
As a result, NRPs exhibit a broad spectrum of biological activities,
ranging from antimicrobial to anticancer (Hur et al., 2012). The
macrocyclic structure is a common feature of nonribosomally
synthesized bioactive peptides, which is responsible for reduction
in structural flexibility and may, therefore, constrain them into
the biologically active conformation (Sieber and Marahiel, 2003;
Grünewald and Marahiel, 2006).
The discovery of NRPs began when Tatum and colleagues
(Mach et al., 1963) provided first evidence that tyrocidine, a cyclic
decapeptide produced by Bacillus brevis, was biosynthesized
by a mechanism independent of the ribosome (Mankelow
and Neilan, 2000). They found that protein synthesis in B.
brevis was inhibited by using ribosome targeting antibiotics
like chloramphenicol and chlortetracycline, however, the
biosynthesis of tyrocidine was not obstructed by the same.
Additional biochemical analyses demonstrated that gramicidin
S, a cyclic decapeptide produced by B.brevis, did not include
tRNA molecules or aminoacyl-tRNA-synthetases (Nikolouli
and Mossialos, 2012; Figure 2). Further work by Lipmann
established that the production of cyclic decapeptide, gramicidin
is an ATP-dependent reaction, catalyzed by these enzymes
incorporating amino acids in a two-step process by their
modules and their respective domains. The first step involves
release of pyrophosphate (PPi) and the second step releases
adenosine monophosphate (AMP), with the end result being
an amino acid covalently linked to the enzyme (Wu et al.,
2003). These finding suggested that tyrocidine and gramicidin S
peptide synthesis did not involve ribosomal machinery for their
synthesis, which leads to discovery of the NRPs and NRPSs.
These data also gave the first indication of an amino acid as a
“carrier” being involved in NRPS enzymology (Felnagle et al.,
2008; Condurso and Bruner, 2012; Figure 3).
The biosynthetic study of NRP compounds is challenging
if we consider their complexity and biological activities. Each
nonribosomal peptide synthetase is composed of an array of
distinct modular sections, each of which is responsible for the
incorporation of one defined monomer into the final peptide
product. Biosynthesis of a nonribosomal peptide by NRPSs
involves a series of repeating reactions that are catalyzed by
the coordinated actions of modules and their core catalytic
domains. Each enzyme module contains three catalytic domains:
adenylation domain (A), peptidyl-carrier (PCP) domain and
condensation domain (C). A final peptide product released
from the enzyme through cyclization or hydrolysis that takes
place by thioesterase domain (TE) which is located in the final
NRPSs module (Figures 4A,B; Mankelow and Neilan, 2000;
Finking and Marahiel, 2004). For recent example, Thiocoraline,
an anticancer nonribosomal peptide (NRP) synthesis by marine
bacteria Cromonospora marina contains peptidic backbone
of two S-methylated Lcysteine residues. S-Methylation occurs
very rarely in nature, and is observed extremely rarely in
nonribosomal peptide scaffold. The four modules TioJ, TioO,
TioR, and TioS of thiocoraline NRPSs are responsible for the
thiocoraline-backbone biosynthesis. TioR and TioS would most
probably constitute the NRPSs involved in the biosynthesis of
the thiocoraline, according to the colinearity of the respective
modules (Figure 5; Lombó et al., 2006; Al-Mestarihi et al.,
2014). The potentials of marine microbes to produce NRP’s
with antimicrobial and anticancer activity are reported in this
review. The data referring to these activities are depicted in
Tables 2–4 and the structures are given in Supplementary
Materials (Figures S1–S17).
NRPS WITH ANTIMICROBIAL POTENTIAL
Antibiotic resistance in bacteria, parasites, viruses and fungi
necessitates the continuous discovery of new drugs for the
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TABLE 1 | List of some marine derived NRPs and their present status (Newman and Cragg, 2004; Fenical, 2006; Jimenez et al., 2009; Petit and Biard, 2013).
Metabolite Source Pharmacological activity R&D stage
Ecteinascidin 743 (YondelisTM) Ecteinascidia turbinate (Sea squirt) Anticancer Market
Cephalosporine Cephalosporium acremonium (Fungi) Antibiotic Market
Bengamide derivative (LAF389) Jaspis sp. (Sponge) Anticancer Phase I
Hemiasterlin derivative (HTI-286) Cymbastella sp. (Sponge) Anticancer Phase I
Dehydrodidemnine B (AplidineTM) Aplidium albicans (Tunicate) Anticancer Phase II
Dolastatin 10 Dolabella auricularia (Mollusc and Cyanobacteria) Anticancer Phase II
Kahalalide F Elysia rufescens (Sea slug) Antitumor Phase II
Bryostatin 1 Bugula neritina (Bryozoan) Anticancer Phase III
Diazonamide Diazona angulata (Tunicate) Anticancer Preclinical
Thiocoraline Mi Cromonospora marina (Bacteria) Anticancer Preclinical
Vitilevuamide Didemnum cucliferum and Polysyncraton lithrostrotum (Tunicates) Anticancer Preclinical
effective prevention and treatment of an ever-increasing range
of infections caused by them (Organization, 2014). Natural
products are the principal source for primary health care.
Natural products are observed as a diverse group of molecules
which have evolved to interact with a wide variety of protein
targets for specific purposes. Also the same protein structure
with little or no variation serves different purposes in different
organisms. As a result, it is believed that the search for
novel antimicrobial entity from natural sources will yield better
results than from combinatorial chemistry and other synthetic
procedures (Ngwoke et al., 2011). Here we described NRPs from
marine microbial sources with antimicrobial potential.
Bacteria
A cationic antibiotic Bogorol A (1) (Figure S1), displaying potent
activity against both methicillin-resistant Staphylococcus aureus
(MRSA, MIC 2µg/mL) and vancomycin-resistant enterococcal
strains (VRE, MIC 10µg/mL) of bacteria, has been isolated from
cultures of a marine Bacillus laterosporus collected in Papua New
Guinea (Barsby et al., 2001). A new broad spectrum thiazolyl
peptide antibiotic, Nocathiacins I–III (2–4) (Figure S1), was
isolated from the cultured broth of Nocardia sp. They share
structural similarities to glycothiohexide-alpha (Li et al., 2003).
All compounds exhibit potent in vitro activity against several
multiple-drug resistant pathogens with MIC of 0.001–0.015,
0.0005–0.25, 0.002–0.06µg/mL respectively. They demonstrate
excellent in vivo efficacy in a systemic S. aureus infection mouse
model at PD50 0.8, 0.6, 0.6 mg/kg/day respectively (Leet et al.,
2003). The marine sponge Halichondria japonica was the source
of Bacillus cereus which gave two cyclic thiopeptide antibiotics,
YM-266183 (5) and YM-266184 (6) (Figure S1). They exhibited
potent antibacterial activity against Staphylococci (MIC 0.05–
0.2µg/mL, 0.013–0.025µg/mL) and Enterococci including
multiple drug resistant strains (MIC 0.02–0.05µg/mL, 0.006–
0.01µg/mL), whereas, they were inactive against gram-negative
bacteria (Nagai et al., 2003). These structures contain thiazole and
pyridine moieties and several unusual amino acids (Suzumura
et al., 2003). A bacterial Ruegeria species isolated from a sponge
Suberites domuncula (Gulf of Naples, Italy), gave two new
cyclic peptides, cyclo-(glycyl-l-seryl-l-prolyl-l- glutamyl) (7) and
cyclo-(glycyl-l-prolyl-l-glutamyl) (8) (Figure S1) with moderate
antimicrobial activity against Bacillus subtilis at MIC of 25 and
50µg/mL, respectively (Mitova et al., 2004). B. laterosporus
PNG276 obtained from Papua New Guinea was the source
of a new lipopeptide antibiotic, Tauramamide (9) (Figure S1).
Anti-pathogenic activity against Enterococcus sp. were reported
for tauramamide and its ethyl ester at MIC 0.1µg/mL
(Desjardine et al., 2007). Pseudomonas sp. separated out from
the seaweed Diginea sp. (Ishigaki Is., Okinawa, Japan) were
the source of cyclic tetrapeptides cyclo-[phenylalanyl-prolyl-
leucyl-prolyl] (10) and cyclo-[isoleucyl-prolyl-leucyl-alanyl] (11)
(Figure S1). The crude extract of this bacterial culture was
found to inhibit the growth of other marine bacterial strains
(Rungprom et al., 2008).
Unnarmicin A (12) and C (13) (Figure S2) are two
depsipeptides isolated from a culture of a marine bacterium,
Photobacterium sp. strainMBIC06485 having selective inhibitory
effect on Pseudovibrio bacterial strains (Oku et al., 2008b).
A strong antibacterial thiopeptide antibiotic TP-1161 (14)
(Figure S2) with a rare aminoacetone moiety, have been
isolated from Nocardiopsis sp. MICs value of TP-1161, ranging
from 0.25 to 4µg/ml for most gram-positive strain. The
gene cluster for the biosynthesis of (14) was identified by
PCR screening using degenerate primers (Engelhardt et al.,
2010). Marine Photobacterium halotolerant yielded two novel
cyclodepsipeptides Solonamide A (15) and B (16) (Figure S2)
with inhibitory effect on virulence gene expression in S.
aureus (Mansson et al., 2011). The fermentation broth of
Streptomyces strain isolated from a marine sediment sample
collected off Nasese, Fiji were the source of three new
depsipeptides, Fijimycins A–C (17–19) (Figure S2). Fijimycins
A–C were shown significant activity against three MRSA strains
with MIC100 values between 4 and 16µg/mL (Sun et al.,
2011). Peptidolipins B–F (20–24) (Figure S2), antibacterial
lipopeptides were obtained from an ascidian-derived Nocardia
sp. Peptide (20) and (23) were moderately antibacterial
against MRSA and methicillin-sensitive S. aureus (MSSA)
(Wyche et al., 2012). A marine-derived bacterium Kocuria
palustris was the source of a new thiazolyl peptide, Kocurin
(25) (Figure S2). Kocurin strongly inhibits MRSA MB5393
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FIGURE 1 | Structures of marketed NRPs.
with a MIC value of 0.25µg/mL (Martín et al., 2013).
An octapeptide, Champacyclin (26) (Figure S2) was isolated
from three strains of Streptomyces champavatii (sediment,
Gotland Deep and Kiel Bight, Baltic Sea and Urania Basin,
Eastern Mediterranean) as an inhibitor of blight disease
causing bacterium Erwinia amylovora (Pesic et al., 2013).
Cyclodepsipeptides Ngercheumicin F–I (27–30) (Figure S2)
isolated from P. halotolerans, inhibited quorum sensing in S.
aureus (Kjaerulff et al., 2013).
Cyanobacteria
Lobocyclamide B (31) (Figure S3) a cyclododecapeptide
containing five beta-hydroxy-alpha-amino acid residues, was
discovered from Lyngbya confervoides which was active against
fluconazole-resistant C. albicans. The absolute stereochemistry
was determined by chiral chromatography of Marfey’s reaction
(MacMillan and Molinski, 2002). Brunsvicamides A–C (32–34)
(Figure S3), three new cyclic hexapeptides have been isolated
from cyanobacterium Tychonema sp. Brunsvicamide C contains
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FIGURE 2 | Tyrocidine biosynthesis in bacteria B. brevis nonribosomal peptide synthetases of tyrocidine synthesis mainly consist, three NRPSs TycA, TycB, and TycC,
which contain 10 modules (TycA comprises one module, TycB three, and TycC six modules) each of those responsible for the incorporation of a cognate amino acid
into the growing chain with the help of their domains. The Te domain at the last module of TycC catalyzes peptide cyclization and thereby release of the final product
(Mootz et al., 2000).
FIGURE 3 | The Gramicidin S biosynthetic machinery the enzymatic assembly consists of two NRPSs (GrsA and GrsB) and their modules, respectively. Each module
is responsible for the incorporation of one monomeric amino acid. The thioesterase domain (TE domain) catalyzes the dimerization of two assembled pentapeptides
and subsequent cyclization, resulting in gramicidin S (Hoyer et al., 2007).
an N-methylated N’-formylkynurenine moiety. Brunsvicamide
B selectively inhibits the Mycobacterium tuberculosis protein
tyrosine phosphatase B (MptpB, IC50 7.3µM) (Müller et al.,
2006).
Fungi
An extraction of a saltwater culture of an unidentifiable
sponge-derived fungus leads to discovering two novel cyclic
depsipeptides, Guangomides A (35) and B (36) (Figure S4).
Both compounds had weak antibacterial activity against
Staphylococcus epidermis (MIC = 100µg/mL, each) and
Enterococcus durans (MIC = 100µg/mL, each) (Amagata
et al., 2006). A marine-derived Aspergillus fumigatus yielded
to 11-O-methylpseurotin A (37) (Figure S4) (PKS/NRPS),
which selectively inhibited a Hof1 deletion strain of the yeast
Saccharomyces cerevisiae (Boot et al., 2007). Marine-derived
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FIGURE 4 | (A) Organization of modules and their domains in nonribosomal peptide synthetase enzyme. Each module contains their catalytic domains that catalyze
activities, substrate activation (A-domain), covalent loading (CP-domain), and peptide bond formation (C-domain). The first modules always lacks a C domain and is
used to initiate nonribosomal peptide synthesis, while those harboring a C-domain qualify for elongation and modules with thioesterase domains (TE) usually in the last
domain, for termination of peptide product from enzyme through cyclization or hydrolysis (Prieto et al., 2012). (B) Mechanism of nonribosomal peptide (NRP) synthesis
Adenylation domain (A) activates amino acid as aminoacyl-AMP and transfer to PCP domain which condenses coming amino acids by forming peptide bonds.
Structural modifications mostly operate by epimerization domains which converts L-amino acid to D-amino acid and vice a versa. Peptide chain thus transfers to TE
domain by transesterification reaction by PCP. Finally, TE domain catalyzed product release (NRPs) by either hydrolysis or macrocyclization (Condurso and Bruner,
2012).
fungus Emericella sp., and marine actinomycete Salinispora
arenicola were co-cultured to induce production of
Emericellamides A (38) and B (39) (Figure S4) by fungi.
Emericellamides A and B displayed modest antibacterial
activities against MRSA with MIC values of 3.8 and 6.0µM,
respectively (Oh et al., 2007).
The fungus Scopulariopsis brevicaulis, isolated from marine
sponge Tethya aurantium was the source of two novel
cyclodepsipeptides, Scopularides A (40) and B (41) (Figure S4),
which were weak inhibitors of gram-positive bacteria (Yu
et al., 2008). Alternaramide (42) (Figure S4), a cyclic Penta
depsipeptide, was produced by culture of Alternaria sp. which
was isolated from sediment, Masan Bay, S. Korea. It’s showed
weak antimicrobial activity against B. subtilis (ZOI 8mm) and
S. aureus (ZOI 13mm) (Kim et al., 2009). Trichoderins A (43),
A1 (44), and B (45) (Figure S4) are three new amino lipopeptides
reported from marine sponge-derived fungus of Trichoderma sp.
All trichoderins have shown potent anti-mycobacterial activity
against Mycobacterium smegmatis, Mycobacterium bovis BCG,
and M. tuberculosis H37Rv under aerobic and dormancy-
inducing hypoxic growth conditions with MIC values in the
range of 0.02–2.0 l g/mL (Pruksakorn et al., 2010).
Aspergillus sp. AF119 was the source of γ-aminobutyric acid
containing cyclic heptapeptide Unguisin E (46) (Figure S4)
(Liu and Shen, 2011). Marine-derived halotolerant Aspergillus
sclerotiorum PT06-1 gave to two novel cyclic hexapeptides
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FIGURE 5 | Structural organization of the thiocoraline NRPSs. L, AMP-ligase; P, peptidyl-carrier protein domain; C, condensation domain; A, adenylation domain; E,
epimerization domain; M, N-methyltransferase domain; TE, thioesterase domain.
Sclerotides A (47) and B (48) (Figure S4) in a nutrient-
limited hypersaline medium. Both of these peptides were photo
inter convertible, containing anthranilic acid, dehydroamino
acid units and showed moderate antifungal activity against C.
albicans. Compound (47) also inhibited P. aeruginosa growth
(Zheng et al., 2009). A halotolerant A. sclerotiorum PT06-1
isolated from salt sediments from the Putian Sea Salt Field,
Fujian, China was the source of 11 new aspochracin-type
cyclic tripeptides, Sclerotiotides A–K (49–59) (Figure S4). Only
sclerotiotides A, B, F and I showed selective antifungal activity
against C. albicans with MIC values of 7.5, 3.8, 30, and 6.7µM,
respectively (Zheng et al., 2010).
NRPS WITH ANTICANCER POTENTIAL
Cancer is the second leading cause of death worldwide. Present
therapies cause serious side effects. Therefore there is need to
employ alternative concepts including natural products therapy,
complementary or alternative medicine, surgery, radiation
therapy used alone or in combination to the prevention of
cancer (Reddy et al., 2003). Here we focus on the marine natural
products specially NRPs that have been evaluated for cancer
prevention.
Bacteria
Three new cytotoxic cyclopeptides, Mixirins A–C (60–62)
(Figure S5) belonging to iturin class have been isolated from
marine bacterium Bacillus sp. obtained from the mud near the
Arctic pole. All compounds inhibited the growth of human
colon tumor cells (HCT-116) with IC50 of 0.68, 1.6, 1.3µg/ml.
(Zhang et al., 2004). A Thermoactinomyces specie YM3-251
have been isolated from mud (Mecherchar, Republic of Palau),
which was the source of a cyclic peptide Mechercharmycin
A (63) as well as the linear congener Mechercharmycin B
(64) (Figure S5). Mechercharmycin A exhibited relatively strong
antitumor activity against A549 cells (human lung cancer) and
Jurkat cells (human leukemia) with IC50 value of 4.0 × 10−8
M and 4.6 × 10−8 M respectively, whereas mechercharmycin B
exhibited no activity (Kanoh et al., 2005). Bromoalterochromides
A and A’ (65–66) (Figure S5), an unprecedented chromo peptide
was produced by a marine Pseudoalteromonas maricaloris strain
KMM 636 which was isolated from sponge Fascaplysinopsis
reticulata. Chemically both of these compounds are brominated
yellow colored Thr-Val-Asn-Asn-X pentapeptide lactones, where
the amino group of Thr is acylated with 9-(3-bromo-4-
hydroxyphenyl)-nona-2, 4,6,8-tetraenoic acid, and X is aIle and
Leu, respectively. They showed moderate cytotoxic effects on
developing eggs of the sea urchin Strongylocentrotus intermedius
(Speitling et al., 2007). New 3-methyl-4-ethylideneproline-
containing cytotoxic peptides, Lucentamycins A–D (67–70)
(Figures S5, S6) have been isolated from the broth of a
marine-derived actinomycete Nocardiopsis lucentensis (strain
CNR-712). Only lucentamycins A and B showed significant
in vitro cytotoxicity against HCT-116 human colon carcinoma
with IC50 values of 0.20 and 11µM, respectively (Cho et al.,
2007).
Three cyclic hexadepsipeptides Piperazimycins A–C (71–73)
(Figure S6) have been isolated from the fermentation broth
of a Streptomyces sp. (sediment, Guam). The structures
of these cyclic hexadepsipeptides have shown presence
of rare amino acids, including hydroxyacetic acid, α-
methylserine, γ-hydroxypiperazic acid, γ-chloropiperazic
acid 2-amino-8-methyl-4, 6-nonadienoic acid, and 2-amino-8-
methyl-4,6-decadienoic acid and were all significantly cytotoxic
against multiple tumor cell lines with an average GI50 76 ng/mL
for each (Miller et al., 2007). The cultured mycelia of marine
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TABLE 2 | Antimicrobial NRPs from marine microbes.
Sr. No. NRPs Chemical
architecture
Source Biological target Biological active value
(MIC/IC50/GI50/ID50/ED50)
References
BACTERIA
1. Bogorol A (1) Linear peptide Bacillus
laterosporus
MRSA, VRE 2µg/mL, 10µg/mL Barsby et al., 2001
2. Nocathiacins I–III (2–4) Cyclic peptide Nocardia sp. multiple-drug
resistant
pathogens
0.001–0.015, 0.0005-0.25,
0.002-0.06µg/mL
Leet et al., 2003;
Li et al., 2003
3. YM- 266183 and YM-
266184 (5–6)
Cyclic peptide Bacillus cereus Staphylococci,
Enterococci
0.05–0.2µg/mL,
0.013–0.025µg/mL.
0.02–0.05µg/mL,
0.006–0.01µg/mL
Nagai et al., 2003;
Suzumura et al.,
2003
4. cyclo-(glycyl-l-seryl-l-prolyl-
l- glutamyl) (7) and
cyclo-(glycyl-l-prolyl-l-
glutamyl) (8)
Cyclic peptide Ruegeria sp. Bacillus subtilis 25 and 50µg/mL Mitova et al., 2004
5. Tauramamide (9) Lipopeptide B. laterosporus Enterococcus sp. 0.1µg/mL Desjardine et al.,
2007
6 Tetrapeptide
cyclo-isoleucyl-prolyl-leucyl
alanyl (10) and cyclo-
phenylalanyl-prolyl-leucyl
prolyl (11)
Cyclic tetra
peptide
Pseudomonas sp. Marine bacterial – Rungprom et al.,
2008
7. Unnarmicin A and C (12–13) Depsipeptide Photobacterium
sp.
Pseudovibrio 7–8µg/mL Oku et al., 2008b
8. Thiopeptide TP-1161 (14) Cyclic peptide Nocardiopsis sp. Gram-positive
bacteria
0.25–4µg/mL Engelhardt et al.,
2010
9. Solonamide A–B (15–16) Cyclo
depsipeptide
Photobacterium
halotolerans
S. aureus – Mansson et al.,
2011
10. Fijimycin A–C (17–19) Depsipeptide Streptomyces sp. MRSA 4–16µg/mL Sun et al., 2011
11. Peptidolipins B–F (20–24) Lipopeptide Nocardia sp. MRSA, MSSA 64µg/mL Wyche et al., 2012
12. Kocurin (25) Cyclic peptide Kocuria palustris MRSA 0.25µg/mL Martín et al., 2013
13. Champacyclin (26) Octapeptide Streptomyces
champavatii
Erwinia amylovora 25µM Pesic et al., 2013
14. Ngercheumicin F–I (27–30) Cyclo
depsipeptide
P. halotolerans S. aureus 5µg/mL Kjaerulff et al.,
2013
CYANOBACTERIA
15. Lobocyclamide B (31) Cyclododecapeptide Lyngbya
confervoides
Fluconazole-
resistant C.
albicans
– MacMillan and
Molinski, 2002
16. Brunsvicamide A–C (32–34) Cyclic hexapeptide Tychonema sp. Mycobacterium
tuberculosis
(MptpB)
7.3µM Müller et al., 2006
FUNGI
17. Guangomides A–B (35–36) Cyclic
depsipeptide
Unidentified
fungus
S. epidermis, E.
durans
100µg/mL 100µg/mL Amagata et al.,
2006
18. 11-O-methylpseurotin A
(37)
Linear peptide Aspergillus
fumigatus
Saccharomyces
cerevisiae
– Boot et al., 2007
19. Emericellamides A–B
(38–39)
Cyclic
depsipeptides
Emericella sp. MRSA 3.8 and 6.0µM Oh et al., 2007
20. Scopularides A–B (40–41) Cyclododecapeptide Scopulariopsis
brevicaulis
Gram-positive
bacteria
– Yu et al., 2008
21. Alternaramide (42) Cyclic Penta
depsipeptide
Alternaria sp.
SF,5016
B. subtilis and S.
aureus
(ZOI 8mm), (ZOI 13mm) Kim et al., 2009
22. Trichoderins A, A’, B2
(43–45)
Lipopeptide Trichoderma sp. Mycobacterium
tuberculosis
0.02–2.0 l g/mL Pruksakorn et al.,
2010
(Continued)
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Sr. No. NRPs Chemical
architecture
Source Biological target Biological active value
(MIC/IC50/GI50/ID50/ED50)
References
23. Unguisin E (46) Cyclic
heptapeptide
Aspergillus sp. Antibacterial – Liu and Shen,
2011
24. Sclerotides A–B (47–48) Cyclic hexapeptide Aspergillus
sclerotiorum
C. albicans,
Pseudomonas
aeruginosa
7.0 and 3.5µM. nil and,
35.3µM
Zheng et al., 2009
25. Sclerotiotides A–K (49–59) Cyclic tripeptide A. sclerotiorum
PT06-1
C. albicans 7.5, 3.8, 30, 6.7µM Zheng et al., 2010
bacterium Mechercharimyces asporophorigenens (marine
lake sediment, Urukthapel Island, Palau) was the source of
Urukthapelstatin A (74) (Figure S6), a cyclic thiopeptide that
displayed potent activity against a human cancer cell line panel.
Urukthapelstatin A has also shown growth inhibition of human
lung cancer A549 cells in dose-dependent manner with an IC
value of 12 nM (Matsuo et al., 2007). The culture of Salinispora
arenicola isolated from sea sediment (Great Astrolabe Reef, Fijiy)
yielded three new cyclohexadepsipeptides, Arenamides A–C
(75–77) (Figure S6). The absolute structures and configuration
of these compounds were established by the spectroscopic
technique. Arenamides A (75) and B (76) blocked tumor
necrosis factor (TNF)-induced activation with IC50 values of 3.7
and 1.7µM respectively. In addition, they also inhibited nitric
oxide and prostaglandin E2 production and were moderately
cytotoxic to HCT-116 cells (Asolkar et al., 2008). Bacillus
silvestris that was isolated from a Pacific Ocean (southern
Chile) crab yields two new cyclodepsipeptides, Bacillistatins
1-2 (78–79) (Figure S6) with strong anti-cancer (GI50 of
10−4-10−5 µg/mL) activity (Pettit et al., 2009). The epimeric
cyclic peptides Turnagainolides A (80) and B (81) (Figure S6),
isolated from marine Bacillus sp. (sediment, Turnagain Is.,
British Columbia, Canada), had indirect inhibitory effect on
phosphatidylinositol-3-kinase (PI3K) pathway (Li et al., 2011).
A Streptomyces sp. obtained from marine sediment produced
two highly modified linear tetrapeptides, Padanamides A (82),
and B (83) (Figure S6). They inhibit cysteine and methionine
biosynthesis and are cytotoxic to Jurkat cells (IC50 of 20µg/mL)
respectively (Williams et al., 2011). Chemical genomics was
performed to discover the mode of action of compounds, which
suggested that padanamide A inhibits cysteine and methionine
biosynthesis.
Streptomyces sp. isolated from volcanic island produced new
cyclic peptides Ohmyungsamycin A (84) and B (85) (Figure S7).
The presence of unusual amino acid units, including N-
methyl-4-methoxytrytophan, β-hydroxyphenylalanine, and N,
N-dimethylvaline in compound (84–85) have been determined
by interpretation of the NMR, UV, and IR spectroscopic and MS
data. Both exhibited inhibitory activities against diverse cancer
cells with IC50 values ranging from 359 to 816 nM and 12.4
to 16.8µM respectively. However, compound (84) was more
active in this regard interestingly; these compounds exhibit
relatively selective anti-proliferative activity against cancer cells
compared to normal cells. This may be due to the consequence of
genetic background or of the biologically various characteristics
between cancer and normal cells. However, the exact molecular
mechanism behind the selectivity should be further investigated
(Um et al., 2013). Proximicins A–C (86–88) (Figure S7) are novel
aminofuran antibiotics with anticancer activity, isolated from
marine strains of verrucosispora sp. Compounds (86–88) showed
inhibitory activity against gastric adenocarcinoma (AGS, IG50
= 0.6, 1.5, 0.25µg/mL respectively), hepatocellular carcinoma
(HepG2, IG50 = 0.8, 9.5, 0.7µg/mL respectively) and breast
carcinoma cells (MCF 7, IG50 = 7.2, 5.0, 9.0µg/mL respectively).
A cell-cycle analysis in AGS cells revealed that Proximicin C
produced cell arrest in the G0/G1 phase after incubation for 24 h.
After 40 h, there was an increase in the number of cells in the sub-
G1 phase, that is, apoptotic cells (+2.9%). It was also found that
proximicin C induce upregulation of p53 and of the cyclin kinase
inhibitor p21 in AGS cells (Fiedler et al., 2008).
Cyanobacteria
An assemblage of Lyngbya majuscula and Phormidium gracile
collected in Papua New Guinea produced a cyclic depsipeptide
Hoiamide A (89) (Figure S8). The highly unusual structure
of hoiamide A synthesized by mixed peptide–polyketide
biosynthetic pathway showed moderate cytotoxicity to cancer
cells and partial agonist of site 2 on the voltage-gated sodium
channel as it produced a rapid and concentration-dependent
elevation of neuronal [Na+] in neocortical neurons (IC50
= 92.8 nM) (Pereira et al., 2009). An assemblage of the
marine cyanobacteria L. majuscula and Schizothrix species
collected from Fiji was the source of cyclic depsipeptides
Yanucamides A (90) and B (91) (Figure S8), which contain
a 2, 2-dimethyl-3-hydroxyoct-7-ynoic acid moiety. Both
compounds exhibited strong brine shrimp toxicity (LD50,
5 ppm) (Sitachitta et al., 2000). The cyclic depsipeptides
named Lyngbyabellins A (92) (Figure S8), contain a 7,7-
dichloro-2,2-dimethyl-3-hydroxyoctanoic acid moiety have
been isolated from the cytotoxic fraction of L. majuscula
collected from Guam and the Dry Tortugas National Park,
Florida. Compound (92) have moderate cytotoxicity against
human nasopharyngeal carcinoma cell line (KB cells) and
human colon adenocarcinoma cell line (LoVo cells), with IC50
values of 0.03 and 0.50µg/mL, respectively and also showed
cellular microfilament network in A-10 cells at 0.01–5.0µg/mL
concentrations (Luesch et al., 2000). Another collection from
Tortugas National Park, Florida was the source of cytotoxic and
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TABLE 3 | Anticancer NRPs from marine microbes.
Sr. No. NRPs Chemical
architecture
Source Biological target Biological active value
(MIC/IC50/GI50/ID50/ED50)
References
BACTERIA
1. Mixirins A–C (60–62) Cyclopeptide Bacillus sp. HCT-116 cells
(colon)
0.68, 1.6, 1.3µg/ml Zhang et al., 2004
2. Mechercharmycin A (63)
Mechercharmycin B (64)
Cyclic peptide Thermoactinomyces
sp.
A549 cells (lung),
Jurkat cells
4.0 × 10−8 M
4.6 × 10−8 M
Kanoh et al., 2005
3. Bromoalterochromide A
(65) and A’ (66)
Chromo peptide Pseudoalteromonas
maricaloris
Strongylocentrotus
intermedius eggs
– Speitling et al.,
2007
4. Lucentamycins A–D
(67–70)
– Nocardiopsis
lucentensis
HCT-116 cells
(colon)
0.20 and 11µM Cho et al., 2007
5. Piperazimycins A–C
(71–73)
Cyclic
hexadepsipeptide
Streptomyces sp. HCT-116 cells
(colon)
76 ng/mL Miller et al., 2007
6. Urukthapelstatin A (74) Cyclic
thiopeptide
Mechercharimyces
asporophorigenens
A549 cells (lung) 12 nM Matsuo et al.,
2007
7. Arenamides A–C (75–77) Cyclo
hexadepsipeptide
Salinispora
arenicola
Tumor necrosis
factor
3.7 and 1.7µM Asolkar et al.,
2008
8. Bacillistatins 1-2 (78–79) Cyclodepsipeptide Bacillus silvestris P388 (murine
lymphocytic
leukemia); BXPC-3
(pancreas); MCF-7
(breast); SF-268
(CNS); NCI- H460
(lung); KM20L2
(colon); DU- 145
(prostate)
10−4−10−5 µg/mL Pettit et al., 2009
9. Turnagainolides A–B
(80–81)
Cyclic peptide Bacillus sp. PI3K pathway – Li et al., 2011
10. Padanamides A–B
(82–83)
Linear
tetrapeptide
Streptomyces sp. Jurkat cells 20µg/mL Williams et al.,
2011
11. Ohmyungsamycins A–B
(84–85)
Cyclic peptide Streptomyces sp. Cytotoxic 359–816 nM and
12.4–16.8µM
Um et al., 2013
12. Proximicin A–C (86–88) – Verrucosispora
strain MG-37
AGS (gastric),
HepG2
(hepatocellular),
MCF 7 (breast)
0.6, 1.5, 0.25µg/mL 0.8,
9.5, 0.7µg/mL 7.2, 5.0,
9.0µg/mL
Fiedler et al., 2008
CYANOBACTERIA
13. Hoiamide A (89) Cyclic
depsipeptide
An assemblage of
L. majuscula and
Phormidium
gracile
Voltage-gated
sodium channel
92.8 nM Pereira et al., 2009
14. Yanucamides A–B
(90–91)
Cyclic
depsipeptide
Lyngbya
majuscule and
Schizothrix sp.
Brine shrimp
toxicity
5 ppm Sitachitta et al.,
2000
15. Lyngbyabellins A (92) Cyclic
depsipeptide
L. majuscula KB cells LoVo cells 0.03 and 0.50µg/mL Luesch et al.,
2000
16. Lyngbyabellin B (93) Cyclic
depsipeptide
L. majuscula Brine shrimp
(Artemia salina)
3.0 ppm Milligan et al.,
2000
17. Microcyclamide (94) Cyclic
hexapeptide
Microcystis
aeruginosa
P388 murine
leukemia cells
24–30µg/mL Ishida et al., 2000
18. Apratoxin A (95) – L. majuscula KB cells and
LoVo cancer cells
0.52 nM
0.36 nM
Luesch et al.,
2001b
19. Pitipeptolides A–B
(96–97)
Cyclic
depsipeptide
L. majuscula LoVo cells 2.25 and 1.95µg/mL Luesch et al.,
2001a
20. Ulongamides A–F
(98–103)
Cyclic
depsipeptide
Lyngbya sp. KB and
LoVo cells
1µM
5µM
Luesch et al.,
2002
21. Obyanamide (104) Cyclic
depsipeptide
L. confervoides KB cells 0.58µg/mL Williams et al.,
2002a
(Continued)
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Sr. No. NRPs Chemical
architecture
Source Biological target Biological active value
(MIC/IC50/GI50/ID50/ED50)
References
22. Malevamide D (105) Linear peptide Symploca
hydnoides
P-388, A-549,
HT-29, and
MEL-28
0.7 and 0.7 nM Horgen et al.,
2002
23. Tasiamide (106) Linear peptide Symploca sp. KB and LoVo cells 0.48 and 3.47µg/mL Williams et al.,
2002b
24. Tasiamide B (107) Linear peptide KB KB cells 0.8µM Williams et al.,
2003a
25. Guineamides A–F
(108–113)
Cyclic
depsipeptide
L. majuscula Mouse
neuroblastoma
cells
15 and 16µM Tan et al., 2003b
26. Homodolastatin 16 (114) Cyclic
depsipeptide
L. majuscula Oesophageal
Cervical cells
4.3µg/mL
1µg/mL
Davies-Coleman
et al., 2003
27. Lyngbyastatin 3 (115) Cyclic peptide L. majuscula KB and LoVo cells 32 and 400 nM Williams et al.,
2003a
28. Ulongapeptin (116) Cyclic
depsipeptide
Lyngbya sp. KB cells 0.63µM Williams et al.,
2003d
29. Tasipeptins A–B
(117–118)
Depsipeptide Symploca sp. KB cells 0.93 and 0.82µM Williams et al.,
2003a
30. Jamaicamides A–C
(119–121)
Lipopeptide L. majuscula H-460 (lung),
Neuro-2a.
Sodium channel
blocking
15µM
5µM
Williams et al.,
2003d
31. Wewakpeptins A–D
(122–125)
Depsipeptide Lyngbya
semiplena
NCI-H460
neuro-2a
0.4µM Williams et al.,
2003b
32. Trungapeptin A–C
(126–128)
Cyclic
depsipeptide
L. majuscula Ichthyotoxic
Brine shrimp
toxicity
6.25 ppm
10 ppm
Bunyajetpong
et al., 2006
33. Aurilides B and C
(129–130)
Cyclic peptide L. majuscula NCI-H460 (lung),
neuro-2a
0.01 and 0.13µM Han et al., 2006
34. Belamide A (131) Tetra peptide Symploca sp. MCF7 (breast)
HCT-116 (colon)
0.74µM Simmons et al.,
2006
35. Lyngbyastatins 5–7
(132–134)
– Lyngbya sp. Potent Elastase
Inhibitors
3–10 nM Taori et al., 2007
36. Mitsoamide (135) Linear peptide Geitlerinema sp. NCI-H460 (lung) 460 nM Andrianasolo
et al., 2007
37. Apratoxin D (136) Cyclic
depsipeptide
L. majuscule and
Lyngbya sordida
H-460 (lung) 2.6 nM Gutiérrez et al.,
2008
38. Apratoxin E (137) – Lyngbya bouillonii HT29 (colon),
HeLa (cervical),
21–72 nM Matthew et al.,
2008
39. Dragonamide C and D
(138–139)
Linear
lipopeptide
Lyngbya polychroa U2OS
(osteosarcoma),
HT29 (colon),
IMR-32
(neuroblastoma)
56 and 59µM
22 and 32µM
49 and 51µM
Gunasekera et al.,
2008
40. Coibamide A (140) Cyclic
depsipeptide
Leptolyngbya sp. NCI 60 cancer cell <23 nM Medina et al.,
2008
41. Symplostatin 4 (141) Linear peptide Symploca sp. Antimitotic to
H-460 (lung)
neuro-2a
40 nM
29nM
Taori et al., 2009
42. Itralamides A–B
(142–143)
Depsipeptide L. majuscula HEK293 cells 6 ± 1µM Jiménez et al.,
2009
43. Desmethoxymajusculamide
C (144)
Cyclic and Liner
peptide
L. majuscula HCT-116 20 nM Simmons et al.,
2009
44. Hantupeptin A (145) Cyclic
depsipeptide
L. majuscula MOLT-4 (leukemia)
MCF-7 (breast)
32µM
4.0µM
Tripathi et al., 2008
45. Desacetyl-Microcolin B
(146)
Linear peptide Lyngbya cf.
polychroa
HT-29 and
IMR-32 cells
14 nM
14nM
Meickle et al.,
2009
(Continued)
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architecture
Source Biological target Biological active value
(MIC/IC50/GI50/ID50/ED50)
References
46. Palmyramide A (147) Cyclic
depsipeptide
L. majuscula Neuro-2a and
H-460
17.2µM
39.7µM
Taniguchi et al.,
2009
47. Bisebromoamide (148) Linear peptide Lyngbya sp. Protein kinase
inhibitor (HeLa S3
cells)
04µg/mL Teruya et al., 2009
48. Lyngbyabellin J (149)
Lyngbyapeptin D (150)
Linear peptide L. bouillonii Actin-disrupting 0.041µM Matthew et al.,
2010
49. Grassypeptolides A–C
(151–153)
Cyclic
depsipeptide
L. confervoides HT29 cells HeLa
cells
1.22µM, 4.97µM, 76.7nM
1.01µM, 2.93µM, 44.6 nM
Kwan et al., 2010
50. Hantupeptin B and C
(154–155)
Cyclodepsipeptide L. majuscula MOLT-4 cells
MCF-7 cells
0.2µM
0.5µM
Tripathi et al., 2010
51. Lyngbyacyclamides A–B
(156–157)
Cyclic peptide Lyngbya sp B16 mouse
melanoma
0.7µM Maru et al., 2010
52. Grassypeptolides D–E
(158–159)
Cyclic
depsipeptide
Leptolyngbya sp. HeLa and
neuro-2a blastoma
335 and 192 nM
599 and 407 nM
Thornburg et al.,
2011
53. Grassypeptolides F and
G (160–161)
Cyclic
depsipeptide
L. majuscula Inhibit transcription
(AP-1 cell)
5.2 and 6.0µM Popplewell et al.,
2011
54. Veraguamides A–H and
J-L (162–172)
– Symploca
hydnoides
H-460 (lung) 141 nM Mevers et al.,
2011; Salvador
et al., 2011
55. Malyngamide 3 (173) and
Cocosamide A–B
(174–175)
Cyclic peptide L. majuscula HT-29 cells 48µM, 24µM, 11µM Gunasekera et al.,
2011
56. Cyclodepsipeptide
(176–180)
Cyclodepsipeptide L. majuscula HT-29 and MCF7 – Montaser et al.,
2010
57. Lagunamide C (181) Cyclodepsipeptide L. majuscula HT-29 and MCF7 2.1–24.4 nM Tripathi et al., 2011
58. Wewakamide A (182)
Guineamide G (183)
Cyclic
depsipeptide
L. semiplena and
L. majuscula
Neuro-2a
blastoma
2.7µM Nan et al., 2011
59. Porpoisamide A–B
(184–185)
Cyclic
depsipeptide
Lyngbya sp. HCT-116 (colon)
cells U2OS
(osteosarcoma)
cells
25, 21µM
28, 22µM
Meickle et al.,
2011
60. Lyngbyabellin K and L
(186–187),
7-epi-lyngbyabellin L
(188) and Lyngbyabellin
M-N (189–190)
Lipopeptide Moorea bouillonii HCT116 (colon)
cells
40.9 ± 3.3 nM Choi et al., 2012
61. Viequeamides A–D
(191–194)
Cyclic
depsipeptide
Rivularia sp. H460 (lung) cells 60 ± 10 nM Boudreau et al.,
2012
62. Symplocin A (195) Linear peptide Symploca sp. Cathepsin E
inhibitor
300 pM Molinski et al.,
2012
63. Bouillonamide (196) Cyclic
depsipeptide
M. bouillonii Neuron 2a cells 6.0µM Tan et al., 2013
64. Malyngamide 4 (197) Lipopeptide Moorea
producens
HTCLs – Shaala et al., 2013
65. Kurahyne B (198) – Okeania sp. HeLa and HL60 8.1 and 9.0µM Okamoto et al.,
2015
FUNGI
66. N-Methylsansalvamide
(199)
Cyclic
depsipeptide
Fusarium strain
CNL-619
Tumor cell 8.3µM Cueto et al., 2000
67. Dictyonamides A–B
(200–201)
Linear
dodecapeptide
Fungus K063 Kinase 4 inhibitor 16.5µg/mL Komatsu et al.,
2001
68. Scytalidamides A–B
(202–203)
Cyclic
heptapeptide
Scytalidium sp. HCT-116 (colon) 7 and 11.0µM Tan et al., 2003a
(Continued)
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69. Trichodermamides A–B
(204–205)
Dipeptide Trichoderma virens HCT-116 (colon) 0.32µg/mL Garo et al., 2003
70. Rostratins A–D
(206–209)
Cyclic dipeptide Exserohilum
rostratum
HCT-116 (colon) 8.5, 1.9, 0.76 and
16.5µg/mL
Tan et al., 2004
71. IB-01212 (210) Cyclic
depsipeptide
Clonostachys sp.
ESNA,A009
LN-caP
(prostrate),
SK-BR3 (breast),
HT29 (colon) and
HELA (cervix)
10-8M Cruz et al., 2006
72. Zygosporamide (211) Cyclic Penta
depsipeptide
Zygosporium
masonii
SF-26 (CNS)
RXF 393 (renal)
6.5 nM
65.0 nM
Oh et al., 2006
73. Trichoderide A (212) – Trichoderma
reesei
A375-S2
melanoma
18.5 mg/mL Sun et al., 2006
74. Spicellamide A–B
(213–214)
Cyclo
hexadepsipeptide
Spicellum roseum Neuron 2a cells 30µg/mL and 6.2µg/mL (Kralj et al., 2007
75. 1962A and 1962B
(215–216)
Cyclic
depsipeptide
Strain No. 1962 MCF-7 (breast) 100µg/mL Huang et al., 2007)
76. Microsporins A–B
(217–218)
Cyclic
tetrapeptide
Microsporum cf.
gypseum
HCT-116, Potent
inhibitors of HDAC
0.6µg/mL and 8.5µg/mL Gu et al., 2007
77. Efrapeptin J (219) Penta
decapeptide
Tolypocladium sp. HT1080 – Hayakawa et al.,
2008
78. Cotteslosin A–B
(220–221)
Cyclo
pentapeptide
Aspergillus
versicolor
MM418c5
(melanoma),
DU145 (prostate),
T47D (breast)
66µg/mL
94µg/mL
90µg/mL
Fremlin et al., 2009
79. Versicotide A–B
(222–223)
Cyclo
pentapeptide
A. versicolor Anti-tumor – Zhou et al., 2011
80. Fellutamide F (224) Lipopeptide A. versicolor SK-MEL-2 (skin)
XF498 (CNS)
HCT15 (Colon)
0.67µM
0.14µM
0.13µM
Lee et al., 2011
81. Cordyheptapeptides C–E
(225–227)
Cyclo
heptapeptide
Acremonium
persicinum
SF-268, MCF-7,
and NCI-H460
2.5–12.1µM Chen et al., 2012
82. Pullularin E and F
(228–229)
– Bionectria
ochroleuca
L5178Y
(lymphoma)
0.1 and 6.7µg/mL Ebrahim et al.,
2012
83. Clavatustides A–C
(230–232)
Cyclodepsipeptide Aspergillus
clavatus
Hepatocellular
Carcinoma Cycle
Inhibitory
– Jiang et al., 2013;
Ye et al., 2014
84. Asperterrestide A (233) Cyclic
tetrapeptide
Aspergillus terreus U937 (carcinoma)
and MOLT4 cell
6.4 and 6.2µM He et al., 2013
85. Similanamide (234) Cyclohexapeptide Aspergillus
similanensis
MCF-7 (breast),
NCI-H460 (lung)
and A373
(melanoma)
125 ± 0
117.50 ± 3.55
115 ± 7.07
Prompanya et al.,
2015
antifungal cyclic depsipeptide Lyngbyabellin B (93) (Figure S8).
Lyngbyabellin B was toxic to brine shrimp (LD50 = 3.0 ppm)
(Milligan et al., 2000). A marine cyanobacterium Microcystis
aeruginosa contained the cyclic hexapeptide Microcyclamide
(94) (Figure S8), which showed moderate cytotoxicity against
P388 murine leukemia cells at 24–30µg/mL (Ishida et al.,
2000).
The cyanobacterium L. majuscule collected from Guam
was the source of Apratoxin A (95) (Figure S8). This
cyclodepsipeptide of mixed peptide-polyketide biogenesis
exhibited in vitro cytotoxicity against human tumor cell lines
at IC50 of 0.36–0.52 nM. Apratoxin A induces G1 phase cell
arrest and apoptosis, which is at least particularly initiated
through antagonism of FGF signaling via STAT3 (Luesch et al.,
2001b). Another collection of L. majuscule from Guam gave
two cyclic depsipeptides, Pitipeptolides A (96) and B (97)
(Figure S8) with anti-mycobacterial and weak cytotoxicity
against LoVo cells with IC50 values of 2.25 and 1.95µg/mL,
respectively. Pitipeptolides A and B also stimulated elastase
activity. It is suggested that this activity is due to the presence
of hydrophobic portions in the molecule (Luesch et al., 2001a).
Marine cyanobacterium Lyngbya sp. collected from Palauan
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TABLE 4 | NRPs with both antimicrobial and anticancer potential from marine microbes.
Sr. No. NRPs Chemical
architecture
Source Biological target Biological active value
(MIC/IC50/GI50/ID50/ED50)
References
1. Lajollamycin (235) Spiro-β-lactone-
γ-lactam
Streptomyces
nodosus
Drug resistant
gram-positive bacteria/
2–20µg/mL Manam et al., 2005
murine melanoma cell
line B16-F10
EC50 of 9.6µM
2. Ariakemicins A-B
(236-237)
Linear peptide Rapidithrix sp S. aureus/ 0.46µg/mL Oku et al., 2008a
human lung cancer
cells (A549) and baby
hamster kidney cells
IC50 values of 25 and
15µg/mL
3. Ieodoglucomide A-B
(238-239)
Glycolipopeptide Bacillus
licheniformis
Antibacterial/lung
cancer and stomach
cancer cell lines
GI50 values of 25.18 and
17.78µg/mL
Tareq et al., 2012
4. Halolitoralin A (240)
Halolitoralins B (241) C
(242)
Cyclic
hexapeptide
Halobacillus
litoralis
Candida albicans and
Tricophyton rubrum/
20, 30, 30µg/mL and 25,
35, 40µg/mL
Yang et al., 2002
Cyclic
tetrapeptide
human gastric tumor
5. Mojavensin A (243) Lipopeptide Bacillus
mojavensis
Valsa mali,
cucumerinum, and
Fusarium verticillioides/
2mg /mL Ma et al., 2012
HL-60 IC50 of 100
6. Marthiapeptide A (244) Cyclic peptide Marinactinospora
thermotolerans
SF-268 (glioblastoma),
MCF-7 (breast),
NCI-H460 (lung),
HepG2
(hepatocarcinoma)/
0.38–0.52µM Zhou et al., 2012
gram-positive bacteria
7. Linear heptapeptide
(245)
Heptapeptide Paenibacillus
profundus
SK-MEL-28 cell / 3.07 µM/ Kalinovskaya et al.,
2013S. aureus, S. epidermis
B. subtilis and
Enterococcus faecium
ZOI = 24mm,
20mm,28mm, 11mm
was the source of six new β-amino acid-containing cyclic
depsipeptides, the Ulongamides A–F (98–103) (Figure S8).
All peptides were found to be weakly cytotoxic against KB
and LoVo cells with IC50 values of ca. 1µM and ca. 5µM
respectively except compound Ulongamides F (Luesch et al.,
2002). Examination of a L. confervoides collection from Saipan,
Commonwealth of the Northern Mariana Islands, led to the
isolation of a novel cytotoxic cyclic depsipeptide Obyanamide
(104) (Figure S8). Obyanamide was cytotoxic against KB cells
with an IC50 of 0.58µg/mL. According to the results, the β-amino
acid residue was found to play a critical role in the biological
activities. Additionally, the ester bond along with the Ala (Thz)
moiety was also essential for biological activities (Williams et al.,
2002a). Malevamide D (105) (Figure S8), a highly cytotoxic
peptide ester have been isolated from marine cyanobacterium
Symploca hydnoides (Horgen et al., 2002). A culture Symploca
sp. yielded Tasiamide (106) (Figure S8), an acyclic peptide.
Tasiamide demonstrated cytotoxic activity against KB and LoVo
cells with IC50 values of 0.48 and 3.47µg/mL, respectively
(Williams et al., 2002b). A new cytotoxic peptide Tasiamide B
(107) (Figure S9) which contain the unusual amino acid-derived
residue 4-amino-3-hydroxy-5-phenylpentanoic acid (Ahppa)
have been isolated from cyanobacterium Symploca sp. This
peptide displayed an IC50 value of 0.8µM against KB cells
(Williams et al., 2003b).
A PapuaNewGuinea collection of themarine cyanobacterium
L. majuscule was the source of six cyclic depsipeptides,
Guineamides A–F (108–113) (Figure S9). The presence of beta-
amino or beta-hydroxy carboxylic acid residues in all peptides
was determined using a combination of chemical manipulations
as well as Marfey’s method. Guineamides B and C showed
moderate cytotoxicty to a mouse neuroblastoma cell line with
IC50 values of 15 and 16µM, respectively (Tan et al., 2003b).
A new bioactive cyclic depsipeptide, Homodolastatin 16 (114)
(Figure S9) have been isolated from L. majuscula, collected from
Wasini Island off the southern Kenyan coast. Homodolastatin
16 showed moderate activity against oesophageal (IC50 =
4.3µg/mL) and cervical cancer cell lines (IC50 = 1µg/mL)
(Davies-Coleman et al., 2003). An examination of an organic
extract of a cyanobacterium L. majuscula, collected from Guam,
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led to the isolation of the cyclic peptide Lyngbyastatin 3
(115) (Figure S9). The presence of two unusual amino acid
units, 3-amino-2-methylhexanoic acid (Amha) and 4-amino-2,
2-dimethyl-3-oxopentanoic acid units (Ibu) was determined by
standard methods. Lyngbyastatin 3 displayed in vitro activity
against KB and LoVo cell lines with IC50 values of 32 and 400 nM
respectively (Williams et al., 2003a).
A collection of Lyngbya sp. from Palauan was the source
of cytotoxic cyclic depsipeptide Ulongapeptin (116) (Figure S9)
with an IC50 value of 0.63µM against KB cells (Williams
et al., 2003d). Two new depsipeptides Tasipeptins A (117)
and B (118) (Figure S9) have been isolated from Palau
collection of Symploca sp. The gross structure of all peptides
(117–118) were determined by standard methods and was
found to contain unusual amino acid-derived residue 4-amino-
3-hydroxy-5-phenylpentanoic acid (Ahppa) and 3-amino-6-
hydroxy-2-piperidone (Ahp) moiety respectively. Both were
cytotoxic toward KB cells with IC50 values of 0.93 and
0.82µM, respectively (Williams et al., 2003c). Lyngbya majuscula
collected from Hector’s Bay, Jamaica was found to contain three
lipopeptides, Jamaicamides A–C (119–121) (Figure S9). Further
biological investigation of the jamaicamides has revealed that
they are generated by iterative hybrid PKS-NRPS assembly and
exhibited cytotoxicity to both the H-460 human lung and Neuro-
2amouse neuroblastoma cell lines (IC50= 15µM for all), sodium
channel blocking activity at 5µM and ichthyotoxic activities
(Edwards et al., 2004). Four new depsipeptides, Wewakpeptins
A–D (122–125) (Figures S9, S10), were found cytotoxic to brine
shrimp and to the NCI-H460 and neuro-2a cell lines (LC50
of approximately 0.4µM). These were isolated from Lyngbya
semiplena collected from Wewak Bay, Papua New Guinea (Han
et al., 2005).
Trungapeptins A-C (126–128) (Figure S10),
cyclodepsipeptides have been isolated from marine
cyanobacterium L. majuscula. Trungapeptin A exhibited
mild icthyotoxicity (6.25 ppm) and weak toxicity to brine
shrimp (10 ppm) (Bunyajetpong et al., 2006). Cytotoxic cyclic
peptides, Aurilides B (129) and C (130) (Figure S10) were
produced by marine cyanobacterium L. majuscula collected
from Papua New Guinea. Both aurilides B and C described to
induce a dysfunction in mitochondria in NCI-H460 human lung
tumor and the neuro-2a mouse neuroblastoma cell lines, with
LC50 values between 0.01 and 0.13µM (Han et al., 2006). A
highly methylated tetrapeptide Belamide A (131) (Figure S10)
was isolated from Symploca sp. (Salmedina Reef, Panama)
which was shown antimitotic and cytotoxic to MCF7 breast
cancer and HCT-116 cell lines (IC50 0.74µM) by microtubule
disruption with structural analogy to the important linear
peptides dolastatins 10 and 15 (Simmons et al., 2006). Three
new analogs of dolastatin 13, Lyngbyastatins 5-7 (132–134)
(Figure S10), have been isolated from two different collections
of marine cyanobacteria, Lyngbya sp., from South Florida with
previously reported cyclodepsipeptide somamide B. Compounds
(132–134) were found to selectively inhibit elastase over several
other serine proteases, with IC50 values for porcine pancreatic
elastase ranging from 3 to 10 nM (Taori et al., 2007). A new linear
peptide Mitsoamide (135) (Figure S10) was produced by marine
cyanobacteriumGeitlerinema sp. collected fromMitso-Ankaraha
Island. Mitsoamide has shown strong activity against NCI-H460
human lung tumor cells with LC50 of 460 nM (Andrianasolo
et al., 2007).
A Papua New Guinea collection of the marine cyanobacteria
L. majuscula and Lyngbya sordida was the source of potent
cytotoxic cyclodepsipeptide Apratoxin D (136) (Figure S10).
Compound (136) possesses 3, 7-dihydroxy-2, 5, 8, 10, 10-
pentamethylundecanoic acid as the polyketide moiety and potent
in vitro cytotoxicity against H-460 human lung cancer cells
with an IC50 value of 2.6 nM (Gutiérrez et al., 2008). Another
collection of marine cyanobacterium Lyngbya bouillonii from a
Guamanianwas found to contain Apratoxin E (137) (Figure S10),
which was strongly cytotoxic to several cancer cell lines at IC50
21–72 nM (Matthew et al., 2008). Dragonamides C (138) and D
(139) (Figures S10, S11) are linear lipopeptides isolated from the
marine cyanobacterium brown Lyngbya polychroa. Both peptides
are weak cytotoxic against several cancer cell lines with GI50
values of 56 and 59µM against U2OS osteosarcoma cells, 22
and 32µM against HT29 colon adenocarcinoma cells, and 49
and 51µM against IMR-32 neuroblastoma cells, respectively
(Gunasekera et al., 2008). Coibamide A (140) (Figure S11), a
potent anti-proliferative highly methylated cyclic depsipeptide
was isolated from a culture of Leptolyngbya sp. which was
collected from the Coiba National Park, Panama. Compound
(140) showed an unprecedented selectivity profile in the NCI 60
cancer cell line panel (LC50 < 23 nM). It causes S phase inhibition
in cell cycle (Medina et al., 2008). Symploca sp. yielded dolastatin
10/15 hybrid linear peptide Symplostatin 4 (141) (Figure S11)
which was shown to be antimitotic activity via microtubule
depolymerization to H-460 lung cancer cells (IC50 = 40 nM) as
well as neuro-2a neuroblastoma cells (IC50 = 29 nM) (Taori et al.,
2009).
A culture of L. majuscule obtained from True Blue Bay,
eastern Caribbean yielded two new depsipeptides, Itralamides A
(142) and B (143) (Figure S11). Only itralamide B was found
to cytotoxic to HEK293 cells IC50 6 ± 1µM (Jiménez et al.,
2009). An active peptide metabolite Desmethoxymajusculamide
C (144) (Figure S11) (DMMC) have been isolated from Fijian
collection of L. majuscule. Both cyclic and liner version of
DMMCwere found potent and showed selective anti-solid tumor
activity at IC50 = 20 nM against HCT-116 through disruption
of cellular microfilament networks (Simmons et al., 2009). A
Singapore collection of L. majuscule has been shown to produce
cyclodepsipeptide, Hantupeptin A (145) (Figure S11) with
cytotoxicity to MOLT-4 leukemia cells (IC50 32µM) and MCF-7
breast cancer cells (IC50 4.0µM) (Tripathi et al., 2008). Chemical
investigation of Lyngbya cf. polychroa resulted in isolation of a
linear peptide desacetylmicrocolin B (146) (Figure S11), was a
growth inhibitor of HT-29 (IC50 14 nM) and IMR-32 cells (IC50
14 nM) (Meickle et al., 2009).
Palmyramide A (147) (Figure S11), a cyclic depsipeptide
found to block sodium channel in neuro-2a cells (IC50 17.2µM)
and modest cytotoxicity to H-460 cells (IC50 39.7µM) and was
isolated from from a Palmyra Atoll Collection of the marine
cyanobacterium L. majuscule (Taniguchi et al., 2009). Lyngbya
sp. was the source of a potent cytotoxic peptide Bisebromoamide
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(148) (Figure S11) which potentially inhibit protein kinase and
is cytotoxic to HeLa S3 cells with an IC50 value of 0.04µg/mL
(Teruya et al., 2009). An examination of an organic extract
of the cyanobacterium L. bouillonii, collected from Guam, led
to the isolation of cytoskeletal actin-disrupting and cytotoxic
(IC50 = 0.041µM) Lyngbyabellin J (149) and a linear modified
peptide, lyngbyapeptin D (150) (Figure S11) (Matthew et al.,
2010). Marine cyanobacterium L. confervoides gave bis-thiazoline
containing cyclic depsipeptides, Grassypeptolides A–C (151-153)
(Figure S12). All grassypeptolides cause G1 phase cell cycle
arrest in HT29 (IC50 = 1.22, 4.97µM, 76.7 nM) and HeLa
cell lines (IC50 = 1.01, 2.93µM, 44.6 nM) (Kwan et al., 2010).
Hantupeptins B (154) and C (155) (Figure S12), two cytotoxic
cyclodepsipeptides were obtained from amarine cyanobacterium
L. majuscule collected from Pulau Hantu Besar, Singapore.
Compound (154) gave an IC50 of 0.2µM against MOLT-4 and
0.5µMagainstMCF-7 cancer cell lines however compound (155)
showed moderate cytotoxicity against the MOLT-4 and MCF-
7 cancer cell lines with IC50 values of 3.0µM and 1.0µM,
respectively (Tripathi et al., 2010). Marine cyanobacteria Lyngbya
sp. was the source of novel cyclic peptides Lyngbyacyclamides A
(156) and B (157) (Figure S12) which moderately inhibited the
growth of B16 mouse melanoma cells (IC50 of 0.7µM) (Maru
et al., 2010).
The marine cyanobacterium Leptolyngbya sp. collected from
the SS Thistlegorm shipwreck in the Red Sea offered two
cyclic depsipeptides, Grassypeptolides D (158) and E (159)
(Figure S12). Both of these peptides were cytotoxic to HeLa
(IC50 = 335 and 192 nM, respectively) and mouse neuro-2a
blastoma cells (IC50 = 599 and 407 nM, respectively) (Thornburg
et al., 2011). Bis-thiazoline-containing cyclic depsipeptides
Grassypeptolides F (160) and G (161) (Figure S12) which
contains rare β-amino acid, extensive N-methylation and a
large number of d-amino acids was isolated from an extract
of Palauan cyanobacterium L. majuscule. Both (160) and (161)
were found to have moderate inhibitory activity against the
transcription factor AP-1 (IC50 = 5.2 and 6.0µM, respectively)
(Popplewell et al., 2011). An examination of an organic extract
of the cyanobacterium Symploca cf. hydnoides sampled from
Cetti Bay, Guam, led to the isolation of the eleven new
peptides Veraguamides A-G (162–168), Veraguamide H (169)
and J–L (170–172) (Figure S12). Veraguamide A showed
potent cytotoxicity to H-460 human lung cancer cell line at
LD50 = 141 nM whilst the others were weak inhibitors. Their
structures were elucidated by combining various techniques in
spectroscopy, chromatography, and synthetic chemistry (Mevers
et al., 2011; Salvador et al., 2011).
Three new cyclic peptides Malyngamide 3 (173) and
Cocosamides A (174) and B (175) (Figure S13) have been
isolated from the lipophilic extract of marine cyanobacteria
L. majuscula collected from Cocos Lagoon, Guam and were
found to modestly cytotoxic to HT-29 cells with IC50 value
of 48, 24, and 11µM respectively (Gunasekera et al., 2011).
L. majuscula (Piti Bomb Holes, Guam) was the source of
proline rich unusual cyclic depsipeptide Pitiprolamide (176)
(Figure S13). Further investigation yielded four more peptides
Pitipeptolides C–F (177–180) (Figure S13). All peptides were
found moderately cytotoxic against two HTCLs, however,
pitipeptolides C–F were more active against M. tuberculosis
and B. cereus as compared to compound (176) (Montaser
et al., 2010). The marine cyanobacterium L. majuscule collected
from western lagoon of Pulau Hantu Besar, Singapore was the
source of cyclodepsipeptide Lagunamide C (181) (Figure S13).
Lagunamide C exhibited potent cytotoxic activity against HTCLs
with IC50 values ranging from 2.1 to 24.4 nM, antimalarial
activity against Plasmodium falciparum (IC50 0.29µM) and weak
anti-swarming activity against P. aeruginosa (Tripathi et al.,
2011).
A collection of marine cyanobacterium L. semiplena and L.
majuscule from Papua New Guinea led to isolation of the cyclic
depsipeptides Wewakamide A (182) and Guineamide G (183)
(Figure S13) were respectively. Both of these peptides displayed
potent toxicity against brine shrimp and only guineamide G
showed cytotoxicity to amouse neuroblastoma cell line with LC50
values of 2.7µM (Nan et al., 2011). A Lyngbya sp. collected in
Florida Keys was found to contain epimeric cyclic depsipeptides
Porpoisamide A (184) and B (185) (Figure S13) which was
weakly cytotoxic to HCT-116 (IC50 = 25, 21µM respectively)
and osteosarcoma U2OS cells (IC50 = 28, 22µM respectively)
(Meickle et al., 2011). Moorea bouillonii (Strawn Is., Palmyra
Atoll, Central Pacific Ocean) gave five lipopeptides Lyngbyabellin
K (186) and L (187), 7-epi-lyngbyabellin L (188) and
Lyngbyabellin M (189) and N (190) (Figure S13). Of note, cyclic
metabolites (189) and (190) possess rare monochlorination on
the 3-acyloxy-2-methyloctanoate residue, whereas unusual N, N-
dimethylvaline containing lyngbyabellinNwas strongly cytotoxic
to HCT116 colon cancer cell line (IC50 = 40.9 ± 3.3 nM) (Choi
et al., 2012). Viequeamides are novel 2, 2-dimethyl-3-hydroxy-
7-octynoic acid (Dhoya)-containing cyclic depsipeptides isolated
from a shallow subtidal collection of a “button” cyanobacterium
Rivularia sp. (Vieques, Puerto Rico). The absolute structures and
configurations of major components Viequeamide A-D (191–
194) (Figures S13, S14) of the mixture were established by
spectroscopic technique. However, viequeamides B–F were not
separated out and only viequeamide A showed high cytotoxicity
against H460 human lung cancer cells at IC50 60 ± 10 nM
(Boudreau et al., 2012). A new N, N-dimethyl-terminated
linear peptide Symplocin A (195) (Figure S14) was produced
by Bahamian collection of cyanobacterium Symploca sp. The
absolute configuration of symplocin A was done by chiral-phase
HPLC of the corresponding 2-naphthacyl esters. Symplocin A
showed potent inhibitory effect on protease enzyme cathepsin
E with IC50 300 pM (Molinski et al., 2012). A collection of
tropical marine cyanobacterium,M. bouillonii, fromNewBritain,
PapuaNewGuinea resulted in isolation of a novel cytotoxic cyclic
depsipeptide, Bouillonamide (196) (Figure S14). Compound
(196) which contains two unique polyketide-derived moieties,
a 2-methyl-6-methylamino-hex-5-enoic acid residue and a unit
of 3-methyl-5-hydroxy-heptanoic acid have shown mild toxicity
against neuron 2a mouse neuroblastoma cells with IC50 6.0µM
(Tan et al., 2013). A new lipopeptides, Malyngamide 4 (197)
(Figure S14) as a moderate inhibitor of several HTCLs have
been isolated from marine cyanobacterium Moorea producens
collected from the Red Sea, Saudi Arabia (Shaala et al., 2013).
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The marine cyanobacteriumOkeania sp. collected from the coast
near Jahana, Okinawa, was the source of Kurahyne B (198)
(Figure S14). It showed growth inhibition against HeLa andHL60
cells, with IC50 values of 8.1 and 9.0µM, respectively (Okamoto
et al., 2015).
Fungi
A culture of marine fungi Fusarium CNL-619 was the source
of a new cyclic depsipeptide N-Methylsansalvamide (199)
(Figure S15), which showed weak in vitro cytotoxicity against
NCI human tumor cell lines (GI50 8.3µM) (Cueto et al.,
2000). An unidentified fungus isolated from the red alga,
Ceradictyon spongiosum (Okinawa) have been shown to produce
two linear dodecapeptides, Dictyonamides A (200) and B (201)
(Figure S15). Only the compound (200) showed inhibitory effect
on cyclin-dependent kinase 4 with IC50 value of 16.5µg/mL
(Komatsu et al., 2001). A culture of marine fungus, Scytalidium
sp., collected from Bahamas was the source of two new cyclic
heptapeptides Scytalidamides A (202) and B (203) (Figure S15)
and both compounds displayed moderate cytotoxicity to the
HCT-116 cell line in vitro with IC50 values of 2.7 and 11.0µM,
respectively (Tan et al., 2003a). A strain ofTrichoderma virenswas
isolated from ascidian Didemnum molle and from the surface of
a green alga of genus Halimeda from Papua New Guinea, which
was the source of two modified dipeptides Trichodermamides
A (204) and B (205) (Figure S15). Trichodermamide B has
showed significant in vitro cytotoxicity against HCT-116 cells
(colon carcinoma) with an IC50 of 0.32µg/mL (Garo et al.,
2003). A fungal strain Exserohilum rostratum associated with a
marine cyanobacterial mat produced four moderately cytotoxic
cyclic dipeptides Rostratins A–D (206–209) (Figure S15).
The structures and absolute configurations of peptides were
determined by two-dimensional NMR techniques and Mosher
method respectively. Compounds (206–209) exhibit activity
against colon carcinoma (HCT-116) with IC50 values of 8.5, 1.9,
0.76, and 16.5µg/mL, respectively (Tan et al., 2004).
A new cytotoxic cyclodepsipeptide, IB-01212 (210)
(Figure S15) was produced by filamentous fungus Clonostachys
sp., ESNA-A009 isolated from an unidentified Japanese
sponge. IB-01212 was potent cytotoxic to several human
tumor cell lines which includes LN-caP (prostrate), SK-BR3
(breast), HT29 (colon), and HELA (cervix) cell lines with GI50
(growth inhibition) in order of 10−8 M (Cruz et al., 2006).
A culture of Zygosporium masonii isolated from a marine
cyanobacterium afforded a new cyclic Penta depsipeptide,
Zygosporamide (211) (Figure S15), which had significant
cytotoxicity in the NCI’s 60 cell line panel, CNS cancer cell
line SF-268 (GI50 = 6.5 nM) and the renal cancer cell line
RXF 393 (GI50 ≤ 5.0 nM) (Oh et al., 2006). Trichoderma
reesei isolated from China, Lianyungang collection of sea
mud produced moderately cytotoxic Trichoderide A (212)
(Figure S15) (Sun et al., 2006). Two new cyclohexadepsipeptides,
Spicellamide A (213) and Spicellamide B (214) (Figure S15)
obtained from fermentation of Spicellum roseum (Ectyplasia
perox, Dominica), exhibited cytotoxicity to neuroblastoma
cells with IC50 value of 30 and 6.2µg/mL respectively
(Kralj et al., 2007). Two new cyclic depsipeptides 1962A,
cyclo-(d-Leu-Gly-l-Tyr-l-Val-Gly-S-O-Leu) (215), and 1962B,
cyclo-(d-Leu-Gly-l-Phe-l-Val-Gly-S-O-Leu) (216) (Figure S15)
have been isolated from the fermentation broth of the mangrove
endophytic fungus isolated from the leaf of Kandelia candel.
Compound (215) only showed activity against human breast
cancer MCF-7 cells with an IC50 value of 100µg/mL (Huang
et al., 2007).
Two new cyclic tetrapeptides Microsporins A (217) and B
(218) (Figure S15) with potent inhibitors of histone deacetylase
(HDAC), cytotoxic to HCT-116 cells (IC50 0.6 and 8.5µg/mL)
was isolated from the marine-derived fungus Microsporum
gypseum (Gu et al., 2007). A Penta decapeptide, Efrapeptin
J (219) (Figure S16), a down-regulator of the molecular
chaperone GRP78 have been isolated from Tolypocladium
sp. (sea mud, Aomori Prefecture, Japan) (Hayakawa et al.,
2008). An Australian marine isolate of Aspergillus versicolor
(MST-MF495) offered two cyclo pentapeptides, Cotteslosins
A (220) and B (221) (Figure S16) (Fremlin et al., 2009). Two
new cyclic pentapeptides, Versicotides A (222) and B (223)
(Figure S16) came from marine fungus strain ZLN-60, identified
as A. versicolor (Zhou et al., 2011). A Cytotoxic lipopeptide
Fellutamide F (224) (Figure S16) have been isolated from the
sponge-derived fungus A. versicolor with cytotoxicity to several
human tumor cells, especially SK-MEL-2 (skin, IC50 0.67µM),
XF498 (CNS, IC50 0.14µM) and HCT15 (Colon, IC50 0.13µM)
(Lee et al., 2011). Fermentation extract of the marine-derived
fungus Acremonium persicinum SCSIO 115 resulted in the
discovery of three new cyclo heptapeptides, Cordyheptapeptides
C–E (225–227) (Figure S16) with cytotoxicity against SF-
268, MCF-7, and NCI-H460 tumor cell line with IC50 values
ranging from 2.5 to 12.1µM (Chen et al., 2012). Chemical
investigation of endophytic fungus Bionectria ochroleuca
isolated from the inner leaf tissues of the plant Sonneratia
caseolaris (Sonneratiaceae) from Hainan Island (China), lead
to discover two new peptides, Pullularins E and F (228-229)
(Figure S16). Both compounds exhibited moderate cytotoxic
activity against the mouse lymphoma cells (L5178Y) with EC50
values ranging between 0.1 and 6.7µg/mL (Ebrahim et al., 2012).
An unusual anthranilic acid dimer and a d-phenyllactic acid
residue containing cyclodepsipeptides Clavatustides A–C (230–
232) (Figure S16) were discovered from cultured mycelia and
broth of Aspergillus clavatus C2WU isolated from Xenograpsus
testudinatus and suppressed proliferation of HTCLs (Jiang
et al., 2013; Ye et al., 2014). Aspergillus terreus SCSGAF0162
gave a new cytotoxic (HTCLs) and antiviral (H1N1 and H3N2)
cyclic tetrapeptide, Asperterrestide A (233) (Figure S16). Which
was cytotoxic toward human carcinoma U937 and MOLT4
cell lines with IC50 values of 6.4 and 6.2µM, respectively, and
also showed inhibitory effects on the influenza virus strains
A/WSN/33 (H1N1) and A/Hong Kong/8/68 (H3N2) with IC50
values of 15 and 8.1µM, respectively (He et al., 2013). A new
cyclohexapeptide, Similanamide (234) (Figure S16) was isolated
from sponge-associated fungus Aspergillus similanensis KUFA
0013 with weak anticancer activity (Prompanya et al., 2015).
Marine microorganisms have been recognized as one of
the most promising groups of organisms from which novel
pharmacologically active molecules, with potential benefits
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against cancer, can be isolated. Recently, several compounds
have been emerged as templates for the development of novel
anticancer drugs. However the mechanisms implicated in the
cytotoxicity of these compounds in tumor cell lines are still
largely overlooked but several studies point to an implication in
apoptosis. For instance, several compounds were found to inhibit
cell growth in a large variety of cancer cell lines, the pathways
by which cancer cells are inhibited are still poorly elucidated.
In some cases, compounds were found to induce cell death by
activation of the apoptotic process; nevertheless the mechanisms
underlying the apoptosis still need more investigations. Some
compounds were found to create an imbalance in cellular redox
potential, with mitochondria representing a central role in the
process. However, more studies are needed in order to clarify it.
Cell cycle is another disturbed process, mainly due to disruption
of the microtubules and actin filaments; however there are
only a few studies connecting marine NRPs with alterations in
cell cycle and more studies are needed in order to clarify the
involvement of these compounds in the process. Even membrane
sodium channels can establish interactions with the compounds,
revealing its potentially important role in the observed effects. In
summary, more investigations are needed in order to clarify the
specific targets and the mechanisms that are behind cancer cell
cytotoxicity, namely the involvement of the apoptotic process by
the implication of functional genomics.
NRPS WITH BOTH ANTIMICROBIAL AND
ANTICANCER POTENTIAL
Lajollamycin, (235) (Figure S17) a nitro-tetraene spiro-β-
lactone-γ-lactam antibiotic have been isolated from marine
actinomycete Streptomyces nodosus. In vitro lajollamycin
inhibited the growth of the murine melanoma cell line B16-
F10 with an EC50 of 9.6µM and also displayed antimicrobial
activity against both drug resistant and sensitive gram-positive
bacteria with MIC 2–20µg/mL (Manam et al., 2005). Two
unusual linear hybrid polyketide-nonribosomal peptide
antibiotics, Ariakemicins A-B (236–237) (Figure S17) have
been isolated from the fermentation broth of the marine
gliding bacterium Rapidithrix sp., (Ariake Inland Sea, Japan).
These antibiotics contain threonine, two omega-amino-
(omega-3)-methyl carboxylic acids with diene or triene units,
and delta-isovanilloylbutyric acid and selectively inhibited
Gram-positive bacteria among which S. aureus was the most
affected (MIC 0.46µg/mL) and were slightly cytotoxic to
human lung cancer cells (A549) and baby hamster kidney
cells with IC50 values of 25 and 15µg/mL respectively (Oku
et al., 2008a). Glycolipopeptides Ieodoglucomide A (238) and
B (239) (Figure S17) have been isolated from marine-derived
bacterium Bacillus licheniformis (sediment, Ieodo Reef, S.
Korea). Compounds (238) and (239) displayed moderately in
vitro antimicrobial activity. However, ieodoglucomide B also
displayed cytotoxic activity against lung cancer and stomach
cancer cell lines with GI50 values of 25.18 and 17.78µg/mL,
respectively (Tareq et al., 2012).
Halolitoralin A (a cyclic hexapeptide) (240) (Figure S17),
Halolitoralin B and C, two cyclic tetrapeptides (241–242)
(Figure S17) were isolated from the marine sediment-derived
Halobacillus litoralis YS3106. All three cyclopeptides show
surprisingly simple architectures with highly repeated residue
units. Compounds (241–242) have shown antifungal activity
against two human fungi Candida albicans and Tricophyton
rubrum with MIC of 20, 30, 30µg/mL and 25, 35, 40µg/mL
respectively. In addition, these three cyclopeptides showed
moderate anti-human gastric tumor activities in vitro (with
a cell line of BGC) (Yang et al., 2002). Bioactivity-guided
fractionation from the fermentation broth of Bacillus mojavensis
B0621A (Pearl oyster Pinctada martensii, Weizhou Is., South
China Sea) was the source of antifungal iturinic lipopeptide
Mojavensin A (243) (Figure S17). The Marfey’s analysis of
mojavensin A provides the novel peptide backbone of L-Asn1, D-
Tyr2, D-Asn3, L-Gln4, L-Pro5, D-Asn6, L-Asn7 and an anteiso-
type of the saturated β-fatty acid side chain. Compound 243
also inhibited the growth of HL-60 with IC50 of 100 (Ma
et al., 2012). A new sequential tristhiazole-thiazoline-containing
cyclic peptide, Marthiapeptide A (244) (Figure S17), have
been isolated from a culture of the deep South China Sea-
derived strain Marinactinospora thermotolerans SCSIO 00652.
Marthiapeptide A exhibited inhibition against a panel of gram-
positive bacteria, with MIC values ranging from 2.0 to 8.0
µg/mL, and displayed strong cytotoxic activity against a panel
of human cancer cell lines with IC50 values ranging from 0.38 to
0.52µM (Zhou et al., 2012). A new linear glyceryl acid derived
heptapeptide (Glyceryl-D-leucyl-D-alanyl-D-leucyl-D-leucyl-L-
valyl-D-leucyl-D-alanine, (245) (Figure S17), were produced
by the culture of marine deep sediment strain Paenibacillus
profundus Sl 79. The compound (245) was cytotoxic to SK-MEL-
28 cell line (IC50 = 3.07µM after 72 h) and also inhibited the
growth of S. aureus (ZOI 24mm), S. epidermis (ZOI 20mm),
B. subtilis (ZOI 28mm) and Enterococcus faecium (ZOI 11mm)
(Kalinovskaya et al., 2013).
ROLE OF GENOMICS, PROTEOMICS AND
BIOINFORMATICS IN DISCOVERY AND
DEVELOPMENT OF NONRIBOSOMAL
PEPTIDES DRUGS
The non-ribosomal peptides (NRPs) are an essential source
of chemical diversity for drug discovery and development. At
present, there are more than 1,164 different non-ribosomal
peptides known in public database (NCBI) which consists of
over 500 unique monomers, including both proteinogenic and
non-proteinogenic L- and D-amino acids as well as carboxylic
acids and amines (Caboche et al., 2010). Due to great structural
diversity (linear, cyclic and branched or other complex primary
structures) these complex secondary metabolites had impact
on all therapeutic area, as making them suitable to be used
as clinical agents. However, such potential NRPs often need
to be modified to improve their clinical properties and/or
bypass resistance mechanisms (Bush, 2012). For instance, FDA
approved Oritavancin has been developed by using semi-
synthesis strategy from Vancomycin for treatment of drug
resistant skin infections (Markham, 2014). Indeed, modification
in the nucleotide sequence of a natural NRPS gene or combining
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modules of different NRPSs may potentially lead them to be
more effective with unique pharmacological activity. However,
this requires in-depth understanding of both the assembly
line and the resulting products. Over the last few decades
several bioengineering approaches have been developed to
increase the yields of NRPs and generating modified peptides
with altered bioactivity or improved physicochemical properties
(Winn et al., 2016). Earlier, biosynthetic generation of novel
NRPs analogs focused on precursor directed biosynthesis (PDB)
or mutasynthesis. In PDB, a wild-type organism is provided
with modified or synthetic amino acids with the prospect that
the substrate specificity of the relevant NRPS shall be flexible
enough to allow addition of the modified precursors into the
final peptide. However, mutasynthesis is the exact opposite. The
modified substrates are fed to an engineered organism which
lacks the enzyme(s) required for the biosynthesis of a specific
natural precursor, so that a modified substrate or precursor
analog may be effectively incorporated (Weist et al., 2004). These
methods are important because they generate natural product
analogs rapidly.
In earlier reviews many examples of precursor directed
biosynthesis of NRPs are available (Thiericke and Rohr, 1993).
Other methods being adopted for the production of new
nonribosomal peptides is engineering of precursor supply in
vivo or introducing tailoring enzymes from other pathways
with new glycosylation, halogenation and sulfation enzymes
being applied outside of their native clusters to create structural
diversity. Although it’s similar to precursor directed biosynthesis,
it focuses mainly on endogenous biosynthesis rather than
exogenous feeding. The introduction of halogen unit into
NRP scaffolds has been a common target. For example, when
the enzyme PrnA (a favin-dependent tryptophan-7-halogenase)
from Pseudomonas fuorescens Pf-5 was expressed alongside
the NRPS genes for the uridyl peptide antibiotic pacidamycin,
produced by Streptomyces coeruleorubidus, a new halogenated
analog was generated (Roy et al., 2010). Using such a technique
enduracidin analogs have been produced by altering halogenase
in wild-type Streptomyces fungicidicus (Yin et al., 2010). An
alternative but complicated strategy has also been developed
to generate novel NRPs. It exchanges NRPS subunit, module,
and domain of the core peptide itself. Initially, this method
was applied by Cubist Pharmaceuticals for the development
and marketing of nonribosomal peptide antibiotic daptomycin,
first natural product antibiotic that gained approval for clinical
use in over 30 years (Baltz et al., 2006). Unfortunately, Cubist
Pharmaceuticals failed to identify any daptomycin variants with
better antibacterial property than parent daptomycin. Another
route that has also been explored which involves modifying the
length of the peptide chain by deletion or insertion of one ormore
modules (Mootz et al., 2002; Butz et al., 2008). A recent study
indicates that the introduction of individual or combined point
mutations in the binding pocket of an NRPS adenylation domain
generates new diversity of NRPs (Han et al., 2012).
A latest technique called heterologous expression offer
considerable promise especially for natural hosts which are
slow growing, genetically difficult to handle, unculturable, or
even unknown. The transfer of biosynthetic genes from the
original microbial organisms to more amenable heterologous
host bacteria is more amenable to large-scale fermentation
production would overcome the limitation of procurement of
the drug from the ocean (which is currently limited to expensive
aquaculture or field harvesting) and ensure supply (Ongley et al.,
2013). The gene cluster responsible for polyketide epothilone (a
potential anticancer agent) biosynthesis in the myxobacterium
Sorangium cellulosum was cloned and completely sequenced by
Tang et al. (2000). Concomitant expression of these genes in
the actinomycete Streptomyces coelicolor produced epothilones
A and B (Tang et al., 2000). After this heterologous expression
system portends a plentiful supply of this medically relevant
agent. Similarly A novel gene (amyZ) encoding a cold-active
and salt-tolerant α-amylase (AmyZ) was cloned from marine
bacterium Zunongwangia profunda (MCCC 1A01486) and the
protein was expressed in Escherichia coli (Qin et al., 2014).
The Ptchi19 gene of the marine Pseudoalteromonas tunicata
CCUG 44952T was cloned and expressed in E.coli (García-Fraga
et al., 2015). A new κ-carrageenase gene from marine bacterium
Zobellia sp. ZM-2 was cloned and expressed in E.coli (Liu et al.,
2013). Heterologous expression of the barbamide biosynthetic
gene cluster from the marine cyanobacteriumMoorea producens
in the terrestrial also led to the production of a new barbamide
congener 4-O-demethylbarbamide (Kim et al., 2012). The
biosynthetic pathway for bacitracin was successfully transferred
from Bacillus licheniformis to the related species B. subtilis
(Eppelmann et al., 2001). The polyketide biosynthesis pathway
for the marine-derived telomerase inhibitor griseorhodin A
was productively transferred to Streptomyces lividans from an
environmental Streptomyces isolate (Li and Piel, 2002). Ugai
et al. (2016) got success in heterologous expression of the
cryptic gene cluster found in A. solani to obtain a marine-
derived antifungal agent didymellamide B from the A. oryzae
transformant introducing PKS–NRPS, trans-ER, and P450 genes
asolSCA (Ugai et al., 2016). Likewise many other successful
examples are available in literature (Fortman and Sherman, 2005;
Luo et al., 2016; Winn et al., 2016).
All studies presented above for production of novel NRPs and
engineering NRPS assembly lines in the native host are laborious
having low throughput and low yield. Recent advances in genome
sequencing, gene synthesis, metabolomics and bioinformatics
revolutionized the process of NRPS engineering. In-silico based
bioprospecting of available microbial genome sequences gives
us a quick look at the hidden biosynthetic capacity of natural
products in the microbial species. Several active as well as
silent enzymes have been identified in fungal and bacterial
genomes which are involved in the biosynthesis of NRPs. The
corresponding secondary metabolites of these enzymes have not
been identified to date (Brakhage, 2013; Doroghazi and Metcalf,
2013). Various powerful computational algorithms and tools have
been developed to analyze BGC and to determine whether they
are likely to encode unique compounds (Medema and Fischbach,
2015). Comprehensive ranges of software tools are available
for identification of BGC in genome sequences. These tools
are generally divided into two categories: high-confidence/low-
novelty and low-confidence/high-novelty. High-confidence/low-
novelty includes tools such as CLUSEAN13, ClustScan14,
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np.searcher15, SMURF16 and antiSMASH (Medema et al.,
2011). These tools analyze Hidden Markov Models (HMMs)
with manually curated cutoffs to identify signature genes
or domains that are highly specific for known classes of
biosynthetic pathways. Such strategies give a quick and reliable
interpretation of NRPs gene cluster of a single strain from its
genome sequence. Low-confidence/high-novelty mainly focuses
on the identification of new BGC types by applying three
approaches; namely pattern-based mining, phylogenetic mining
and comparative genomic mining. These further include Cluster
Finder, EvoMining, and Algorithim, respectively. Tools for
identification of BGCs with respect to metagenomes include
PCR-based sequence-tag and the shotgun assembly approach.
The sequence-tag approach identifies clones from selected
harbor pathways in metagenomic libraries by amplifying known
biosynthetic domains using PCR. This is particularly useful for
identifying variants of known pathway types. This has been
also used to identify gene clusters encoding close relatives of
molecule such as rapamycin, teicoplanin, and thiocoraline (Owen
et al., 2013). However, the tag-based approach can be used to
find entirely new molecules that are produced by known BGC
classes, especially when coupled with phylogenomic tools such
as NaPDoS (Ziemert et al., 2012). These tools find application
in identifying domains that represent new areas of the extant
biosynthetic diversity. A range of systems have been developed to
predict the substrate specificities of NRPS adenylation domains
(Röttig et al., 2011; Prieto et al., 2012). Tools such as NP.searcher
and antiSMASH individual monomer predictions are then
combined to give a rough idea of the core scaffold of a
nonribosomal peptide. Simultaneously, advancement in mass
spectrometry gives efficient dereplication for analysis of small-
molecule products of biosynthetic pathways (Nielsen and Larsen,
2015). NRPQuest algorithm usesmolecular networking approach
to identify potential gene clusters for observed tandem mass
spectra of NRPs (Mohimani et al., 2014). The search database for
NRPquest generates all possible orders of NRPS assembly lines
within each detected NRP BGC hence, predicting the amino acids
encoded by each of its module using NRPSPredictor2 (Röttig
et al., 2011). A chemoinformatic based library and informatic
search strategy for natural products (iSNAP) has also been
doveloped for true nontargeted dereplication across a spectrum
of nonribosomal peptides and within natural product extracts
(Ibrahim et al., 2012). It is clear that the tools and techniques
discussed above have accelerated the discovery and development
of novel NRPs with desirable biological activities.
CONCLUSION AND FUTURE PROSPECTS
OF MARINE DERIVED NONRIBOSOMAL
PEPTIDES
Marine chemicals often possess quite novel structures which
in turn lead to pronounced biological activity and novel
pharmacology. The study of such chemicals, therefore, is a
very promising endeavor. There are three parallel branches
in marine natural products chemistry: marine biomedicinals,
marine chemical ecology and marine toxins. Integration of
these three fields of study gives marine natural products
chemistry its exclusive character and vigor. The search among
marine chemicals for medically useful agents involves two steps,
discovering the type of biological activity and studying the
pharmacological mechanism of the activity. It is now clear that
efforts to date in marine natural product chemistry have largely
focused on easily collected microorganisms and their major
metabolites, and while there has been a recent shift to, as detailed
above, minor metabolites present in very small quantities are a
challenge for analytical and biological evaluations.
As has been demonstrated in this review, the potential for
nonribosomal peptides from marine as sources and/or leads
to drugs that have pharmacological effects (i.e., cancer and
anti-infective) is only now being realized. Combining enzyme
technology and solid phase peptide synthesis, it is possible to
generate a vast variety of unique peptides composed of non-
proteinogenic amino acids with unique pharmacological and
biotherapeutic potential. It is possible that in coming years at
least one or more marine derived novel nonribosomal peptide
will enter into commerce as a drug. In concluding, the huge
ranges of nonribosomal peptides that have so far been identified
frommarine resources frequently have no comparable equivalent
in terrestrial organisms. The work by (predominately) young
investigators on the many aspects of nonribosomal peptides
(like biosynthesis) in the commensal and/or symbiotic microbes
associated with these invertebrates, or in the microbes isolated
from shallow and deep sediments will increase the numbers
of nonribosomal peptides from marine for further work. The
marine system has hardly been scratched as yet!
AUTHOR CONTRIBUTIONS
SA collected the available bibliographic information and wrote
the manuscript. AA and CB conceived the study. SD and DA
reviewed the collected information critically.
FUNDING
Deakin University provided a postgraduate scholarship to SA.
ACKNOWLEDGMENTS
The authors are grateful to TERI Deakin Nano biotechnology
Centre, Biotechnology and Bioresources Division, The Energy
and Resources Institute, India for continuous support.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fphar.
2017.00828/full#supplementary-material
Frontiers in Pharmacology | www.frontiersin.org 20 November 2017 | Volume 8 | Article 828
Agrawal et al. Nonribosomal Peptides from Marine Microbes
REFERENCES
Agrawal, S., Adholeya, A., and Deshmukh, S. K. (2016). The pharmacological
potential of non-ribosomal peptides from marine sponge and tunicates. Front.
Pharmacol. 7:333. doi: 10.3389/fphar.2016.00333
Al-Mestarihi, A. H., Villamizar, G. N., Fernández, J., Zolova, O. E., Lombó, F., and
Garneau-Tsodikova, S. (2014). Adenylation and S-methylation of cysteine by
the bifunctional enzyme TioN in thiocoraline biosynthesis. J. Am. Chem. Soc.
136, 17350–17354. doi: 10.1021/ja510489j
Amagata, T., Morinaka, B. I., Amagata, A., Tenney, K., Valeriote, F. A., Lobkovsky,
E., et al. (2006). A chemical study of cyclic depsipeptides produced by
a sponge-derived fungus. J. Nat. Prod. 69, 1560–1565. doi: 10.1021/np06
0178k
Andrianasolo, E. H., Goeger, D., and Gerwick, W. H. (2007). Mitsoamide: a
cytotoxic linear lipopeptide from the Madagascar marine cyanobacterium
Geitlerinema sp. Pure Appl. Chem. 79, 593–602. doi: 10.1351/pac200779
040593
Asolkar, R. N., Freel, K. C., Jensen, P. R., Fenical, W., Kondratyuk, T. P.,
Park, E.-J., et al. (2008). Arenamides A– C, Cytotoxic NFκB Inhibitors from
the Marine Actinomycete Salinispora arenicola? J. Nat. Prod. 72, 396–402.
doi: 10.1021/np800617a
Baltz, R. H., Brian, P., Miao, V., and Wrigley, S. K. (2006). Combinatorial
biosynthesis of lipopeptide antibiotics in Streptomyces roseosporus. J. Indus.
Microbiol. Biotechnol. 33, 66–74. doi: 10.1007/s10295-005-0030-y
Barsby, T., Kelly, M. T., Gagné, S. M., and Andersen, R. J. (2001). Bogorol
A produced in culture by a marine Bacillus sp. reveals a novel template
for cationic peptide antibiotics. Organ. Lett. 3, 437–440. doi: 10.1021/ol00
6942q
Blunt, J. W., Copp, B. R., Keyzers, R. A., Munro, M., and Prinsep,
M. R. (2015). Marine natural products. Nat. Prod. Rep. 32, 116–211.
doi: 10.1039/C4NP00144C
Boot, C. M., Gassner, N. C., Compton, J. E., Tenney, K., Tamble, C. M., Lokey, R.
S., et al. (2007). Pinpointing pseurotins from a marine-derived Aspergillus as
tools for chemical genetics using a synthetic lethality yeast screen. J. Nat. Prod.
70, 1672–1675. doi: 10.1021/np070307c
Boudreau, P. D., Byrum, T., Liu, W.-T., Dorrestein, P. C., and Gerwick, W. H.
(2012). Viequeamide A, a cytotoxic member of the kulolide superfamily of
cyclic depsipeptides from a marine button cyanobacterium. J. Nat. Prod. 75,
1560–1570. doi: 10.1021/np300321b
Brakhage, A. A. (2013). Regulation of fungal secondary metabolism. Nat. Rev.
Microbiol. 11, 21–32. doi: 10.1038/nrmicro2916
Bunyajetpong, S., Yoshida, W. Y., Sitachitta, N., and Kaya, K. (2006).
Trungapeptins AC, cyclodepsipeptides from the marine cyanobacterium
Lyngbya majuscula. J. Nat. Prod. 69, 1539–1542. doi: 10.1021/np050485a
Bush, K. (2012). Improving known classes of antibiotics: an optimistic
approach for the future. Curr. Opin. Pharmacol. 12, 527–534.
doi: 10.1016/j.coph.2012.06.003
Butz, D., Schmiederer, T., Hadatsch, B., Wohlleben, W., Weber, T., and Süssmuth,
R. D. (2008). Module extension of a non-ribosomal peptide synthetase of the
glycopeptide antibiotic balhimycin produced by Amycolatopsis balhimycina.
Chembiochem 9, 1195–1200. doi: 10.1002/cbic.200800068
Caboche, S., Leclère, V., Pupin, M., Kucherov, G., and Jacques, P. (2010). Diversity
of monomers in nonribosomal peptides: towards the prediction of origin and
biological activity. J. Bacteriol. 192, 5143–5150. doi: 10.1128/JB.00315-10
Caboche, S., Pupin, M., Leclere, V., Fontaine, A., Jacques, P., and Kucherov, G.
(2008). NORINE: a database of nonribosomal peptides. Nucleic Acids Res. 36,
D326–D331. doi: 10.1093/nar/gkm792
Caboche, S., Pupin, M., Leclère, V., Jacques, P., and Kucherov, G. (2009).
Structural pattern matching of nonribosomal peptides. BMC Struct. Biol. 9:1.
doi: 10.1186/1472-6807-9-15
Chen, Z., Song, Y., Chen, Y., Huang, H., Zhang, W., and Ju, J. (2012). Cyclic
Heptapeptides, Cordyheptapeptides C–E, from the Marine-Derived Fungus
Acremonium persicinum SCSIO 115 and Their Cytotoxic Activities. J. Nat.
Prod. 75, 1215–1219. doi: 10.1021/np300152d
Cho, J. Y., Williams, P. G., Kwon, H. C., Jensen, P. R., and Fenical, W. (2007).
Lucentamycins AD, cytotoxic peptides from the marine-derived actinomycete
Nocardiopsis lucentensis. J. Nat. Prod. 70, 1321–1328. doi: 10.1021/np070101b
Choi, H., Mevers, E., Byrum, T., Valeriote, F. A., and Gerwick, W. H. (2012).
Lyngbyabellins K–N from two Palmyra atoll collections of the marine
cyanobacterium Moorea bouillonii. European J. Org. Chem., 2012, 5141–5150.
doi: 10.1002/ejoc.201200691
Condurso, H. L., and Bruner, S. D. (2012). Structure and noncanonical chemistry of
nonribosomal peptide biosynthetic machinery. Nat. Prod. Rep. 29, 1099–1110.
doi: 10.1039/c2np20023f
Cruz, L. J., Insua, M. M., Baz, J. P., Trujillo, M., Rodriguez-Mias, R. A., Oliveira,
E., et al. (2006). IB-01212, a new cytotoxic cyclodepsipeptide isolated from the
marine fungus Clonostachys sp. ESNA-A009. J. Organ. Chem. 71, 3335–3338.
doi: 10.1021/jo051600p
Cueto, M., Jensen, P. R., and Fenical, W. (2000). N-Methylsansalvamide, a
cytotoxic cyclic depsipeptide from a marine fungus of the genus Fusarium.
Phytochemistry 55, 223–226. doi: 10.1016/S0031-9422(00)00280-6
Davies-Coleman, M. T., Dzeha, T. M., Gray, C. A., Hess, S., Pannell, L. K.,
Hendricks, D. T., et al. (2003). Isolation of Homodolastatin 16, a New Cyclic
Depsipeptide from a Kenyan Collection of Lyngbya m ajuscula. J. Nat. Prod. 66,
712–715. doi: 10.1021/np030014t
Desjardine, K., Pereira, A., Wright, H., Matainaho, T., Kelly, M., and Andersen,
R. J. (2007). Tauramamide, a lipopeptide antibiotic produced in culture by
Brevibacillus laterosporus isolated from a marine habitat: structure elucidation
and synthesis. J. Nat. Prod. 70, 1850–1853. doi: 10.1021/np070209r
Doroghazi, J. R., and Metcalf, W. W. (2013). Comparative genomics of
actinomycetes with a focus on natural product biosynthetic genes. BMC
Genomics 14:611. doi: 10.1186/1471-2164-14-611
Ebrahim, W., Kjer, J., El Amrani, M., Wray, V., Lin, W., Ebel, R., et al. (2012).
Pullularins E and F, two new peptides from the endophytic fungus Bionectria
ochroleuca isolated from the mangrove plant Sonneratia caseolaris.Mar. Drugs
10, 1081–1091. doi: 10.3390/md10051081
Edwards, D. J., Marquez, B. L., Nogle, L. M., Mcphail, K., Goeger, D. E., Roberts,
M. A., et al. (2004). Structure and biosynthesis of the jamaicamides, new mixed
polyketide-peptide neurotoxins from the marine cyanobacterium Lyngbya
majuscula. Chem. Biol. 11, 817–833. doi: 10.1016/j.chembiol.2004.03.030
Engelhardt, K., Degnes, K. F., Kemmler,M., Bredholt, H., Fjaervik, E., Klinkenberg,
G., et al. (2010). Production of a new thiopeptide antibiotic, TP-1161, by
a marine Nocardiopsis species. Appl. Environ. Microbiol. 76, 4969–4976.
doi: 10.1128/AEM.00741-10
Eppelmann, K., Doekel, S., and Marahiel, M. A. (2001). Engineered biosynthesis of
the peptide antibiotic bacitracin in the surrogate host Bacillus subtilis. J. Biol.
Chem. 276, 34824–34831. doi: 10.1074/jbc.M104456200
Felnagle, E. A., Jackson, E. E., Chan, Y. A., Podevels, A. M., Berti, A. D.,
Mcmahon, M. D., et al. (2008). Nonribosomal peptide synthetases involved in
the production of medically relevant natural products.Mol. Pharm. 5, 191–211.
doi: 10.1021/mp700137g
Fenical, W. (2006). Marine pharmaceuticals: past, present, and future.
Oceanography 2, 110–119. doi: 10.5670/oceanog.2006.74
Fiedler, H.-P., Bruntner, C., Riedlinger, J., Bull, A. T., Knutsen, G., Goodfellow, M.,
et al. (2008). Proximicin A, B andC, novel aminofuran antibiotic and anticancer
compounds isolated from marine strains of the actinomycete Verrucosispora.
J. Antibiot. 61, 158–163. doi: 10.1038/ja.2008.125
Finking, R., and Marahiel, M. A. (2004). Biosynthesis of
nonribosomal peptides1. Annu. Rev. Microbiol. 58, 453–488.
doi: 10.1146/annurev.micro.58.030603.123615
Fortman, J., and Sherman, D. H. (2005). Utilizing the power of microbial genetics
to bridge the gap between the promise and the application of marine natural
products. ChemBioChem 6, 960–978. doi: 10.1002/cbic.200400428
Fremlin, L. J., Piggott, A.M., Lacey, E., and Capon, R. J. (2009). Cottoquinazoline A
and cotteslosins A and B, metabolites from an Australian marine-derived strain
of Aspergillus versicolor. J. Nat. Prod. 72, 666–670. doi: 10.1021/np800777f
García-Fraga, B., Da Silva, A. F., López-Seijas, J., and Sieiro, C. (2015). A
novel family 19 chitinase from the marine-derived Pseudoalteromonas tunicata
CCUG 44952T: heterologous expression, characterization and antifungal
activity. Biochem. Eng. J. 93, 84–93. doi: 10.1016/j.bej.2014.09.014
Garo, E., Starks, C. M., Jensen, P. R., Fenical, W., Lobkovsky, E., and Clardy,
J. (2003). Trichodermamides A and B, cytotoxic modified dipeptides from
the marine-derived fungus Trichoderma virens. J. Nat. Prod. 66, 423–426.
doi: 10.1021/np0204390
Frontiers in Pharmacology | www.frontiersin.org 21 November 2017 | Volume 8 | Article 828
Agrawal et al. Nonribosomal Peptides from Marine Microbes
Grünewald, J., and Marahiel, M. A. (2006). Chemoenzymatic and template-
directed synthesis of bioactive macrocyclic peptides. Microbiol. Mol. Biol. Rev.
70, 121–146. doi: 10.1128/MMBR.70.1.121-146.2006
Gu, W., Cueto, M., Jensen, P. R., Fenical, W., and Silverman, R. B. (2007).
Microsporins A and B: new histone deacetylase inhibitors from the marine-
derived fungus Microsporum cf. gypseum and the solid-phase synthesis
of microsporin A. Tetrahedron 63, 6535–6541. doi: 10.1016/j.tet.2007.
04.025
Gunasekera, S. P., Owle, C. S., Montaser, R., Luesch, H., and Paul, V. J. (2011).
Malyngamide 3 and cocosamides A and B from the marine cyanobacterium
Lyngbya majuscula from Cocos Lagoon, Guam. J. Nat. Prod. 74, 871–876.
doi: 10.1021/np1008015
Gunasekera, S. P., Ross, C., Paul, V. J., Matthew, S., and Luesch, H. (2008).
Dragonamides C and D, linear lipopeptides from the marine cyanobacterium
brown Lyngbya polychroa. J. Nat. Prod. 71, 887–890. doi: 10.1021/np07
06769
Gutiérrez, M., Suyama, T. L., Engene, N., Wingerd, J. S., Matainaho, T., and
Gerwick, W. H. (2008). Apratoxin D, a potent cytotoxic cyclodepsipeptide
from Papua New Guinea collections of the marine cyanobacteria Lyngbya
majuscula and Lyngbya sordida. J. Nat. Prod. 71, 1099–1103. doi: 10.1021/np80
0121a
Han, B., Goeger, D., Maier, C. S., and Gerwick, W. H. (2005). The
Wewakpeptins, Cyclic Depsipeptides from a Papua New Guinea Collection of
the Marine Cyanobacterium Lyngbya s emiplena. J. Org. Chem. 70, 3133–3139.
doi: 10.1021/jo0478858
Han, B., Gross, H., Goeger, D. E., Mooberry, S. L., and Gerwick, W. H. (2006).
Aurilides B and C, Cancer Cell Toxins from a Papua New Guinea Collection
of the Marine Cyanobacterium Lyngbya m ajuscula. J. Nat. Prod. 69, 572–575.
doi: 10.1021/np0503911
Han, J. W., Kim, E. Y., Lee, J. M., Kim, Y. S., Bang, E., and Kim, B.
S. (2012). Site-directed modification of the adenylation domain of the
fusaricidin nonribosomal peptide synthetase for enhanced production of
fusaricidin analogs. Biotechnol. Lett. 34, 1327–1334. doi: 10.1007/s10529-012-
0913-8
Hayakawa, Y., Hattori, Y., Kawasaki, T., Kanoh, K., Adachi, K., Shizuri,
Y., et al. (2008). Efrapeptin J, a new down-regulator of the molecular
chaperone GRP78 from a marine Tolypocladium sp. J. Antibiot. 61, 365–371.
doi: 10.1038/ja.2008.51
He, F., Bao, J., Zhang, X.-Y., Tu, Z.-C., Shi, Y.-M., and Qi, S.-H. (2013).
Asperterrestide A, a cytotoxic cyclic tetrapeptide from the marine-derived
fungus Aspergillus terreus SCSGAF0162. J. Nat. Prod. 76, 1182–1186.
doi: 10.1021/np300897v
Hedgepeth, J. (1957). Sandy Beaches. Penrose: Geological Society of America.
Horgen, F. D., Kazmierski, E. B., Westenburg, H. E., Yoshida, W. Y., and
Scheuer, P. J. (2002). Malevamide D: isolation and structure determination of
an isodolastatin H Analogue from the Marine Cyanobacterium Symploca h
ydnoides. J. Nat. Prod. 65, 487–491. doi: 10.1021/np010560r
Hoyer, K. M., Mahlert, C., and Marahiel, M. A. (2007). The iterative gramicidin s
thioesterase catalyzes peptide ligation and cyclization. Chem. Biol. 14, 13–22.
doi: 10.1016/j.chembiol.2006.10.011
Hranueli, D., Žucˇko, J., Diminic´, J., and Starcˇevic´, A. (2010). From DNA
sequences to chemical structures–Methods for mining microbial genomic and
metagenomic datasets for new natural products. Food Technol. Biotechnol. 48,
234–242.
Huang, H., She, Z., Lin, Y., Vrijmoed, L., and Lin, W. (2007). Cyclic peptides from
an endophytic fungus obtained from a mangrove leaf (Kandelia candel). J. Nat.
Prod. 70, 1696–1699. doi: 10.1021/np0605891
Hur, G. H., Vickery, C. R., and Burkart, M. D. (2012). Explorations of catalytic
domains in non-ribosomal peptide synthetase enzymology. Nat. Prod. Rep. 29,
1074–1098. doi: 10.1039/c2np20025b
Ibrahim, A., Yang, L., Johnston, C., Liu, X., Ma, B., and Magarvey, N. A. (2012).
Dereplicating nonribosomal peptides using an informatic search algorithm
for natural products (iSNAP) discovery. Proc. Natl. Acad. Sci. U.S.A. 109,
19196–19201. doi: 10.1073/pnas.1206376109
Ishida, K., Nakagawa, H., and Murakami, M. (2000). Microcyclamide, a Cytotoxic
Cyclic Hexapeptide from the Cyanobacterium Microcystis a eruginosa. J. Nat.
Prod. 63, 1315–1317. doi: 10.1021/np000159p
Jiang, W., Ye, P., Chen, C.-T. A., Wang, K., Liu, P., He, S., et al. (2013). Two
novel hepatocellular carcinoma cycle inhibitory cyclodepsipeptides from a
hydrothermal vent crab-associated fungus Aspergillus clavatus C2WU. Mar.
Drugs 11, 4761–4772. doi: 10.3390/md11124761
Jiménez, J. I., Vansach, T., Yoshida, W. Y., Sakamoto, B., PöRzgen, P., and Horgen,
F. D. (2009). Halogenated fatty acid amides and cyclic depsipeptides from an
eastern caribbean collection of the cyanobacterium Lyngbya majuscula†. J. Nat.
Prod. 72, 1573–1578. doi: 10.1021/np900173d
Jimenez, J. T., Sturdíkova, M., and Studik, E. (2009). Natural products of marine
origin and their perspectives in the discovery of new anticancer drugs. Acta
Chim. Slov. 2, 63–74.
Jimeno, J., Faircloth, G., Sousa-Faro, J., Scheuer, P., and Rinehart, K. (2004). New
marine derived anticancer therapeutics–a journey from the sea to clinical trials.
Mar. Drugs 2, 14–29. doi: 10.3390/md201014
Kalinovskaya, N. I., Romanenko, L. A., Kalinovsky, A. I., Dmitrenok, P. S., and
Dyshlovoy, S. A. (2013). A new antimicrobial and anticancer peptide producing
by the marine deep sediment strain “Paenibacillus profundus” sp. nov. Sl 79.
Nat. Prod. Commun. 8, 381–384.
Kanoh, K., Matsuo, Y., Adachi, K., Imagawa, H., Nishizawa, M., and
Shizuri, Y. (2005). Mechercharmycins A and B, cytotoxic substances from
marine-derived Thermoactinomyces sp. YM3-251. J. Antib. 58, 289–292.
doi: 10.1038/ja.2005.36
Kim, E. J., Lee, J. H., Choi, H., Pereira, A. R., Ban, Y. H., Yoo, Y. J., et al. (2012).
Heterologous production of 4-O-demethylbarbamide, a marine cyanobacterial
natural product. Org. Lett. 14, 5824–5827. doi: 10.1021/ol302575h
Kim, M.-Y., Sohn, J. H., Ahn, J. S., and Oh, H. (2009). Alternaramide, a cyclic
depsipeptide from the marine-derived fungus Alternaria sp. SF-5016. J. Natl.
Products 72, 2065–2068. doi: 10.1021/np900464p
Kjaerulff, L., Nielsen, A., Mansson, M., Gram, L., Larsen, T. O., Ingmer, H.,
et al. (2013). Identification of four new agr quorum sensing-interfering
cyclodepsipeptides from amarine Photobacterium.Mar. Drugs, 11, 5051–5062.
doi: 10.3390/md11125051
Komatsu, K., Shigemori, H., and Kobayashi, J. I. (2001). Dictyonamides A and
B, new peptides from marine-derived fungus. J. Org. Chem. 66, 6189–6192.
doi: 10.1021/jo0156767
Kralj, A., Kehraus, S., Krick, A., Van Echten-Deckert, G., and König, G. M. (2007).
Two New Depsipeptides from the Marine Fungus Spicellum roseum. Planta
Med. 73, 366–371. doi: 10.1055/s-2007-967131
Kubanek, J., Jensen, P. R., Keifer, P. A., Sullards, M. C., Collins, D. O., and
Fenical, W. (2003). Seaweed resistance to microbial attack: a targeted chemical
defense against marine fungi. Proc. Natl. Acad. Sci. U.S.A. 100, 6916–6921.
doi: 10.1073/pnas.1131855100
Kwan, J. C., Ratnayake, R., Abboud, K. A., Paul, V. J., and Luesch, H.
(2010). Grassypeptolides A–C, cytotoxic bis-thiazoline containing marine
cyclodepsipeptides. J. Org. Chem. 75, 8012–8023. doi: 10.1021/jo1013564
Lee, Y.-M., Li, J., Zhang, P., Hong, J.-K., Lee, C.-O., and Jung, J.-H.
(2011). A cytotoxic fellutamide analogue from the sponge-derived
fungus Aspergillus versicolor. Bullet. Korean Chem. Soc. 32, 3817–3820.
doi: 10.5012/bkcs.2011.32.10.3817
Leet, J. E., Li, W., Ax, H. A., Matson, J. A., Huang, S., Huang, R., et al.
(2003). Nocathiacins, new thiazolyl peptide antibiotics from Nocardia sp. II.
Isolation, characterization, and structure determination. J. Antib. 56, 232–242.
doi: 10.7164/antibiotics.56.232
Li, A., and Piel, J. (2002). A gene cluster from a marine Streptomyces encoding the
biosynthesis of the aromatic spiroketal polyketide griseorhodin A. Chem. Biol.
9, 1017–1026. doi: 10.1016/S1074-5521(02)00223-5
Li, D., Carr, G., Zhang, Y., Williams, D. E., Amlani, A., Bottriell, H., et al. (2011).
Turnagainolides A and B, cyclic depsipeptides produced in culture by a Bacillus
sp.: isolation, structure elucidation, and synthesis. J. Nat. Prod. 74, 1093–1099.
doi: 10.1021/np200033y
Li, W., Leet, J. E., Ax, H. A., Gustavson, D. R., Brown, D. M., Turner, L.,
et al. (2003). Nocathiacins, new thiazolyl peptide antibiotics from Nocardia
sp. I. Taxonomy, fermentation and biological activities. J. Antib. 56, 226–231.
doi: 10.7164/antibiotics.56.226
Liu, S., and Shen, Y. (2011). A new cyclic peptide from the marine
fungal strain Aspergillus sp. AF119. Chem. Natl. Compounds 47, 786–788.
doi: 10.1007/s10600-011-0059-2
Frontiers in Pharmacology | www.frontiersin.org 22 November 2017 | Volume 8 | Article 828
Agrawal et al. Nonribosomal Peptides from Marine Microbes
Liu, Z., Li, G., Mo, Z., and Mou, H. (2013). Molecular cloning, characterization,
and heterologous expression of a new κ-carrageenase gene from marine
bacterium Zobellia sp. ZM-2. Appl. Microbiol. Biotechnol. 97, 10057–10067.
doi: 10.1007/s00253-013-5215-0
Lombó, F., Velasco, A., Castro, A., de la Calle, F., Braña, A. F., Sánchez-
Puelles, J. M., et al. (2006). Deciphering the biosynthesis pathway of the
antitumor thiocoraline from a marine actinomycete and its expression in
two Streptomyces species. Chembiochem 7, 366–376. doi: 10.1002/cbic.2005
00325
Luesch, H., Pangilinan, R., Yoshida, W. Y., Moore, R. E., and Paul, V.
J. (2001a). Pitipeptolides A and B, new cyclodepsipeptides from the
marine cyanobacterium Lyngbya majuscula. J. Nat. Prod. 64, 304–307.
doi: 10.1021/np000456u
Luesch, H., Williams, P. G., Yoshida, W. Y., Moore, R. E., and Paul, V. J. (2002).
Ulongamides AF, New β-Amino Acid-Containing Cyclodepsipeptides from
Palauan Collections of the Marine Cyanobacterium Lyngbya sp. J. Nat. Prod.
65, 996–1000. doi: 10.1021/np0200461
Luesch, H., Yoshida, W. Y., Moore, R. E., Paul, V. J., and Corbett, T. H. (2001b).
Total Structure Determination of Apratoxin A, a Potent Novel Cytotoxin
from the Marine Cyanobacterium Lyngbya m ajuscula. J. Am. Chem. Soc. 123,
5418–5423. doi: 10.1021/ja010453j
Luesch, H., Yoshida, W. Y., Moore, R. E., Paul, V. J., and Mooberry, S. L. (2000).
Isolation, Structure Determination, and Biological Activity of Lyngbyabellin
A from the Marine Cyanobacterium Lyngbya m ajuscula. J. Nat. Prod. 63,
611–615. doi: 10.1021/np990543q
Luo, Y., Enghiad, B., and Zhao, H. (2016). New tools for reconstruction
and heterologous expression of natural product biosynthetic
gene clusters. Nat. Prod. Rep. 33, 174–182. doi: 10.1039/C5NP0
0085H
Ma, Z., Wang, N., Hu, J., and Wang, S. (2012). Isolation and characterization
of a new iturinic lipopeptide, mojavensin A produced by a marine-
derived bacterium Bacillus mojavensis B0621A. J. Antibiot. 65, 317–322.
doi: 10.1038/ja.2012.19
Mach, B., Reich, E., and Tatum, E. (1963). Separation of the biosynthesis of the
antibiotic polypeptide tyrocidine from protein biosynthesis. Proc. Natl. Acad.
Sci. U.S.A. 50:175. doi: 10.1073/pnas.50.1.175
MacMillan, J. B., and Molinski, T. F. (2002). Lobocyclamide B from Lyngbya
confervoides. Configuration and Asymmetric Synthesis of β-Hydroxy-α-amino
Acids by (-)-Sparteine-Mediated Aldol Addition. Organ. Lett. 4, 1883–1886.
doi: 10.1021/ol025876k
Manam, R. R., Teisan, S., White, D. J., Nicholson, B., Grodberg, J., Neuteboom,
S. T., et al. (2005). Lajollamycin, a Nitro-tetraene Spiro-β-lactone-γ-lactam
Antibiotic from the Marine Actinomycete Streptomyces n odosus. J. Nat. Prod.
68, 240–243. doi: 10.1021/np049725x
Mankelow, D. P., and Neilan, B. A. (2000). Non-ribosomal peptide
antibiotics. Exp. Opin. Ther. Pat. 10, 1583–1591. doi: 10.1517/13543776.10.
10.1583
Mansson, M., Nielsen, A., Kjærulff, L., Gotfredsen, C. H., Wietz, M., Ingmer, H.,
et al. (2011). Inhibition of virulence gene expression in Staphylococcus aureus by
novel depsipeptides from a marine Photobacterium.Mar. Drugs 9, 2537–2552.
doi: 10.3390/md9122537
Markham, A. (2014). Oritavancin: first global approval. Drugs 74, 1823–1828.
doi: 10.1007/s40265-014-0295-4
Martín, J., Da S Sousa, T., Crespo, G., Palomo, S., González, I., Tormo,
J. R., et al. (2013). Kocurin, the true structure of PM181104, an anti-
methicillin-resistant Staphylococcus aureus (MRSA) thiazolyl peptide from
the marine-derived bacterium Kocuria palustris. Mar. Drugs, 11, 387–398.
doi: 10.3390/md11020387
Maru, N., Ohno, O., and Uemura, D. (2010). Lyngbyacyclamides A and B, novel
cytotoxic peptides frommarine cyanobacteria Lyngbya sp.Tetrahedron Lett. 51,
6384–6387. doi: 10.1016/j.tetlet.2010.06.105
Matsunaga, S., and Fusetani, N. (2003). Nonribosomal peptides from
marine sponges. Curr. Org. Chem. 7, 945–966. doi: 10.2174/13852720334
86648
Matsuo, Y., Kanoh, K., Yamori, T., Kasai, H., Katsuta, A., Adachi, K., et al.
(2007). Urukthapelstatin A, a novel cytotoxic substance from marine-derived
Mechercharimyces asporophorigenens YM11-542. J. Antibiot. 60, 251–255.
doi: 10.1038/ja.2007.30
Matthew, S., Salvador, L. A., Schupp, P. J., Paul, V. J., and Luesch, H. (2010).
Cytotoxic halogenated macrolides and modified peptides from the apratoxin-
producing marine cyanobacterium Lyngbya bouillonii from Guam. J. Nat.
Prod. 73, 1544–1552. doi: 10.1021/np1004032
Matthew, S., Schupp, P. J., and Luesch, H. (2008). Apratoxin E, a cytotoxic
peptolide from a Guamanian collection of the marine cyanobacterium Lyngbya
bouillonii. J. Nat. Prod. 71, 1113–1116. doi: 10.1021/np700717s
Medema, M. H., and Fischbach, M. A. (2015). Computational approaches
to natural product discovery. Nat. Chem. Biol. 11, 639–648.
doi: 10.1038/nchembio.1884
Medema, M. H., Blin, K., Cimermancic, P., De Jager, V., Zakrzewski, P., Fischbach,
M. A., et al. (2011). antiSMASH: rapid identification, annotation and analysis of
secondary metabolite biosynthesis gene clusters in bacterial and fungal genome
sequences. Nucleic Acids Res. 39, W339–W346. doi: 10.1093/nar/gkr466
Medina, R. A., Goeger, D. E., Hills, P., Mooberry, S. L., Huang, N., Romero, L. I.,
et al. (2008). Coibamide A, a potent antiproliferative cyclic depsipeptide from
the Panamanian marine cyanobacterium Leptolyngbya sp. J. Am. Chem. Soc.
130, 6324–6325. doi: 10.1021/ja801383f
Meickle, T., Gunasekera, S. P., Liu, Y., Luesch, H., and Paul, V. J. (2011).
Porpoisamides A and B, two novel epimeric cyclic depsipeptides from a
Florida Keys collection of Lyngbya sp. Bioorg. Med. Chem. 19, 6576–6580.
doi: 10.1016/j.bmc.2011.05.051
Meickle, T., Matthew, S., Ross, C., Luesch, H., and Paul, V. (2009). Bioassay-
guided isolation and identification of desacetyl-microcolin B from Lyngbya cf.
polychroa. Planta Med. 75:1427. doi: 10.1055/s-0029-1185675
Mevers, E., Liu, W.-T., Engene, N., Mohimani, H., Byrum, T., Pevzner, P.
A., et al. (2011). Cytotoxic veraguamides, alkynyl bromide-containing cyclic
depsipeptides from the marine cyanobacterium cf. Oscillatoria margaritifera.
J. Natl. Products 74, 928–936. doi: 10.1021/np200077f
Miller, E. D., Kauffman, C. A., Jensen, P. R., and Fenical, W. (2007).
Piperazimycins: cytotoxic hexadepsipeptides from a marine-derived bacterium
of the genus Streptomyces. J. Org. Chem. 72, 323–330. doi: 10.1021/jo061064g
Milligan, K. E., Marquez, B. L., Williamson, R. T., and Gerwick, W. H. (2000).
Lyngbyabellin B, a Toxic and Antifungal Secondary Metabolite from the
Marine Cyanobacterium Lyngbya m ajuscula. J. Nat. Prod. 63, 1440–1443.
doi: 10.1021/np000133y
Mitova, M., Popov, S., and De Rosa, S. (2004). Cyclic peptides from a Ruegeria
strain of bacteria associated with the sponge Suberites domuncula. J. Nat. Prod.
67, 1178–1181. doi: 10.1021/np049900+
Mohimani, H., Liu, W.-T., Kersten, R. D., Moore, B. S., Dorrestein, P. C., and
Pevzner, P. A. (2014). NRPquest: coupling mass spectrometry and genome
mining for nonribosomal peptide discovery. J. Nat. Prod. 77, 1902–1909.
doi: 10.1021/np500370c
Molinski, T. F., Reynolds, K. A., and Morinaka, B. I. (2012). Symplocin A, a linear
peptide from the bahamian cyanobacterium Symploca sp. configurational
analysis of N, N-Dimethylamino acids by chiral-phase HPLC of naphthacyl
esters. J. Natl. Products 75, 425–431. doi: 10.1021/np200861n
Montaser, R., Abboud, K. A., Paul, V. J., and Luesch, H. (2010). Pitiprolamide, a
proline-rich dolastatin 16 analogue from the marine cyanobacterium Lyngbya
majuscula from Guam. J. Nat. Prod. 74, 109–112. doi: 10.1021/np1006839
Mootz, H. D., Kessler, N., Linne, U., Eppelmann, K., Schwarzer, D., and Marahiel,
M. A. (2002). Decreasing the ring size of a cyclic nonribosomal peptide
antibiotic by in-frame module deletion in the biosynthetic genes. J. Am. Chem.
Soc. 124, 10980–10981. doi: 10.1021/ja027276m
Mootz, H. D., Schwarzer, D., and Marahiel, M. A. (2000). Construction of hybrid
peptide synthetases bymodule and domain fusions. Proc. Natl. Acad. Sci. U.S.A.
97, 5848–5853. doi: 10.1073/pnas.100075897
Müller, D., Krick, A., Kehraus, S., Mehner, C., Hart, M., Küpper, F. C., et al.
(2006). Brunsvicamides AC: sponge-related cyanobacterial peptides with
Mycobacterium tuberculosis protein tyrosine phosphatase inhibitory activity.
J. Med. Chem. 49, 4871–4878. doi: 10.1021/jm060327w
Nagai, K., Kamigiri, K., Arao, N., Suzumura, K.-I., Kawano, Y., Yamaoka, M., et al.
(2003). YM-266183 and YM-266184, novel thiopeptide antibiotics produced
by Bacillus cereus isolated from a marine sponge. I. Taxonomy, fermentation,
isolation, physico-chemical properties and biological properties. J. Antibiot. 56,
123–128. doi: 10.7164/antibiotics.56.123
Nan, H. B., Mcphail, K. L., and Maier, C. S. (2011). Wewakamide A and
guineamide G, cyclic depsipeptides from the marine cyanobacteria lyngbya
Frontiers in Pharmacology | www.frontiersin.org 23 November 2017 | Volume 8 | Article 828
Agrawal et al. Nonribosomal Peptides from Marine Microbes
semiplena and lyngbya majuscula. J. Microbiol. Biotechnol. 21, 930–936.
doi: 10.4014/jmb.1105.05011
Newman, D. J., and Cragg, G. M. (2004). Marine natural products and related
compounds in clinical and advanced preclinical trials. J. Nat. Prod. 67,
1216–1238. doi: 10.1021/np040031y
Ngwoke, K. G., Odimegwu, D. C., and Esimone, C. (2011). Antimicrobial Natural
Products. Science agaianst Microbial Pathogens: Communicating Current
Research and Technology Advances. Badajoz: FORMATEX.
Nielsen, K. F., and Larsen, T. O. (2015). The importance of mass spectrometric
dereplication in fungal secondary metabolite analysis. Front. Microbiol. 6:71.
doi: 10.3389/fmicb.2015.00071
Nikolouli, K., and Mossialos, D. (2012). Bioactive compounds synthesized by
non-ribosomal peptide synthetases and type-I polyketide synthases discovered
through genome-mining and metagenomics. Biotechnol. Lett. 34, 1393–1403.
doi: 10.1007/s10529-012-0919-2
Oh, D.-C., Jensen, P. R., and Fenical, W. (2006). Zygosporamide, a cytotoxic cyclic
depsipeptide from the marine-derived fungus Zygosporiummasonii. Tetrahedr.
Lett. 47, 8625–8628. doi: 10.1016/j.tetlet.2006.08.113
Oh, D.-C., Kauffman, C. A., Jensen, P. R., and Fenical, W. (2007). Induced
production of emericellamides A and B from the marine-derived fungus
Emericella sp. in competing co-culture. J. Natl. Products 70, 515–520.
doi: 10.1021/np060381f
Okamoto, S., Iwasaki, A., Ohno, O., and Suenaga, K. (2015). Isolation and structure
of kurahyne B and total synthesis of the kurahynes. J. Nat. Prod. 78, 2719–2725.
doi: 10.1021/acs.jnatprod.5b00662
Oku, N., Adachi, K., Matsuda, S., Kasai, H., Takatsuki, A., and Shizuri, Y.
(2008a). Ariakemicins A and B, novel polyketide-peptide antibiotics from a
marine gliding bacterium of the genus Rapidithrix. Org. Lett. 10, 2481–2484.
doi: 10.1021/ol8007292
Oku, N., Kawabata, K., Adachi, K., Katsuta, A., and Shizuri, Y. (2008b).
Unnarmicins A and C, new antibacterial depsipeptides produced by
marine bacterium Photobacterium sp. MBIC06485. J. Antibiot. 61, 11–17.
doi: 10.1038/ja.2008.103
Ongley, S. E., Bian, X., Neilan, B. A., and Müller, R. (2013). Recent advances in the
heterologous expression of microbial natural product biosynthetic pathways.
Nat. Prod. Rep. 30, 1121–1138. doi: 10.1039/c3np70034h
Organization, W. H. (2014). Antimicrobial Resistance: Global Report on
Surveillance. Geneva: World Health Organization.
Owen, J. G., Reddy, B. V. B., Ternei, M. A., Charlop-Powers, Z., Calle, P. Y., Kim,
J. H., et al. (2013). Mapping gene clusters within arrayed metagenomic libraries
to expand the structural diversity of biomedically relevant natural products.
Proc. Natl. Acad. Sci. U.S.A. 110, 11797–11802. doi: 10.1073/pnas.12221
59110
Pereira, A., Cao, Z., Murray, T. F., and Gerwick, W. H. (2009). Hoiamide
a, a sodium channel activator of unusual architecture from a consortium
of two papua new Guinea cyanobacteria. Chem. Biol. 16, 893–906.
doi: 10.1016/j.chembiol.2009.06.012
Pesic, A., Baumann, H. I., Kleinschmidt, K., Ensle, P., Wiese, J., Süssmuth, R.
D., et al. (2013). Champacyclin, a New Cyclic Octapeptide from Streptomyces
Strain C42 Isolated from the Baltic Sea. Mar. Drugs 11, 4834–4857.
doi: 10.3390/md11124834
Petit, K., and Biard, J.-F. (2013). Marine natural products and related compounds
as anticancer agents: an overview of their clinical status.Anticancer AgentsMed.
Chem. 13, 603–631. doi: 10.2174/1871520611313040010
Pettit, G. R., Knight, J. C., Herald, D. L., Pettit, R. K., Hogan, F., Mukku, V. J.,
et al. (2009). Antineoplastic Agents. 570. Isolation and Structure Elucidation of
Bacillistatins 1 and 2 from a Marine Bacillus silvestris† ,‡. J. Natl. Products 72,
366–371. doi: 10.1021/np800603u
Pfennig, S., and Stubbs, M. T. (2012). Flexing and stretching in
nonribosomal Peptide synthetases. Chem. Biol. 19, 167–169.
doi: 10.1016/j.chembiol.2012.02.002
Popplewell, W. L., Ratnayake, R., Wilson, J. A., Beutler, J. A., Colburn, N. H.,
Henrich, C. J., et al. (2011). Grassypeptolides F and G, cyanobacterial peptides
from Lyngbya majuscula. J. Nat. Prod. 74, 1686–1691. doi: 10.1021/np20
05083
Prieto, C., García-Estrada, C., Lorenzana, D., and Martín, J. F. (2012).
NRPSsp: non-ribosomal peptide synthase substrate predictor. Bioinformatics
28, 426–427. doi: 10.1093/bioinformatics/btr659
Prompanya, C., Fernandes, C., Cravo, S., Pinto, M. M., Dethoup, T., Silva, A.,
et al. (2015). A new cyclic hexapeptide and a new isocoumarin derivative from
the marine sponge-associated fungus Aspergillus similanensisKUFA 0013.Mar.
Drugs 13, 1432–1450. doi: 10.3390/md13031432
Pruksakorn, P., Arai, M., Kotoku, N., Vilcheze, C., Baughn, A. D., Moodley, P.,
et al. (2010). Trichoderins, novel aminolipopeptides from a marine sponge-
derived Trichoderma sp., are active against dormant mycobacteria. Bioorg.
Med. Chem. Lett. 20, 3658–3663. doi: 10.1016/j.bmcl.2010.04.100
Qin, Y., Huang, Z., and Liu, Z. (2014). A novel cold-active and salt-tolerant α-
amylase from marine bacterium Zunongwangia profunda: molecular cloning,
heterologous expression and biochemical characterization. Extremophiles 18,
271–281. doi: 10.1007/s00792-013-0614-9
Reddy, L., Odhav, B., and Bhoola, K. (2003). Natural products for
cancer prevention: a global perspective. Pharmacol. Ther. 99, 1–13.
doi: 10.1016/S0163-7258(03)00042-1
Röttig, M., Medema, M. H., Blin, K., Weber, T., Rausch, C., and Kohlbacher,
O. (2011). NRPSpredictor2—a web server for predicting NRPS
adenylation domain specificity. Nucleic Acids Res. 39, W362–W367.
doi: 10.1093/nar/gkr323
Roy, A. D., GrüSchow, S., Cairns, N., and Goss, R. J. (2010). Gene
expression enabling synthetic diversification of natural products: chemogenetic
generation of pacidamycin analogs. J. Am. Chem. Soc. 132, 12243–12245.
doi: 10.1021/ja1060406
Rungprom, W., Siwu, E. R., Lambert, L. K., Dechsakulwatana, C., Barden, M. C.,
Kokpol, U., et al. (2008). Cyclic tetrapeptides from marine bacteria associated
with the seaweed Diginea sp. and the spongeHalisarca ectofibrosa. Tetrahedron
64, 3147–3152. doi: 10.1016/j.tet.2008.01.089
Salvador, L. A., Biggs, J. S., Paul, V. J., and Luesch, H. (2011). Veraguamides A–
G, cyclic hexadepsipeptides from a dolastatin 16-producing cyanobacterium
Symploca cf. hydnoides from Guam. J. Natl. Products 74, 917–927.
doi: 10.1021/np200076t
Shaala, L. A., Youssef, D. T., Mcphail, K. L., and Elbandy, M. (2013). Malyngamide
4, a new lipopeptide from the Red Sea marine cyanobacterium Moorea
producens (formerly Lyngbya majuscula). Phytochem. Lett. 6, 183–188.
doi: 10.1016/j.phytol.2013.01.002
Sieber, S. A., and Marahiel, M. A. (2003). Learning from nature’s drug factories:
nonribosomal synthesis of macrocyclic peptides. J. Bacteriol. 185, 7036–7043.
doi: 10.1128/JB.185.24.7036-7043.2003
Simmons, T. L., Mcphail, K. L., Ortega-Barría, E., Mooberry, S. L., and
Gerwick, W. H. (2006). Belamide A, a new antimitotic tetrapeptide from
a Panamanian marine cyanobacterium. Tetrahedron Lett. 47, 3387–3390.
doi: 10.1016/j.tetlet.2006.03.082
Simmons, T. L., Nogle, L. M., Media, J., Valeriote, F. A., Mooberry, S. L.,
and Gerwick, W. H. (2009). Desmethoxymajusculamide C, a cyanobacterial
depsipeptide with potent cytotoxicity in both cyclic and ring-opened forms. J.
Nat. Prod. 72, 1011–1016. doi: 10.1021/np9001674
Sitachitta, N., Williamson, R. T., and Gerwick, W. H. (2000). Yanucamides A and
B, Two New Depsipeptides from an Assemblage of the Marine Cyanobacteria
Lyngbya m ajuscula and Schizothrix Species. J. Nat. Prod. 63, 197–200.
doi: 10.1021/np990466z
Speitling, M., Smetanina, O. F., Kuznetsova, T. A., and Laatsch, H. (2007).
Bromoalterochromides A and A
′
, Unprecedented Chromopeptides from a
Marine Pseudoalteromonas maricaloris Strain KMM 636T†. J. Antibiot. 60,
36–42. doi: 10.1038/ja.2007.5
Strieker, M., Tanovic, A., and Marahiel, M. A. (2010). Nonribosomal peptide
synthetases: structures and dynamics. Curr. Opin. Struct. Biol. 20, 234–240.
doi: 10.1016/j.sbi.2010.01.009
Sun, P., Maloney, K. N., Nam, S.-J., Haste, N. M., Raju, R., Aalbersberg, W.,
et al. (2011). Fijimycins A–C, three antibacterial etamycin-class depsipeptides
from a marine-derived Streptomyces sp. Bioorg. Med. Chem. 19, 6557–6562.
doi: 10.1016/j.bmc.2011.06.053
Sun, Y., Tian, L., Huang, Y.-F., Sha, Y., and Pei, Y.-H. (2006). A new
cyclotetrapeptide from marine fungus Trichoderma reesei. Die Pharm. Int. J.
Pharm. Sci. 61, 809–810.
Suzumura, K.-I., Yokoi, T., Funatsu, M., Nagai, K., Tanaka, K., Zhang, H., et al.
(2003). YM-266183 and YM-266184, novel thiopeptide antibiotics produced
by Bacillus cereus isolated from a marine sponge II. Structure elucidation. J.
Antibiot. 56, 129–134. doi: 10.7164/antibiotics.56.129
Frontiers in Pharmacology | www.frontiersin.org 24 November 2017 | Volume 8 | Article 828
Agrawal et al. Nonribosomal Peptides from Marine Microbes
Tan, L. T., Cheng, X. C., Jensen, P. R., and Fenical, W. (2003a). Scytalidamides
A and B, new cytotoxic cyclic heptapeptides from a marine fungus of
the genus Scytalidium. J. Org. Chem. 68, 8767–8773. doi: 10.1021/jo03
0191z
Tan, L. T., Okino, T., and Gerwick, W. H. (2013). Bouillonamide: a mixed
polyketide–peptide cytotoxin from the Marine Cyanobacterium Moorea
bouillonii.Mar. Drugs 11, 3015–3024. doi: 10.3390/md11083015
Tan, L. T., Sitachitta, N., and Gerwick, W. H. (2003b). The Guineamides,
Novel Cyclic Depsipeptides from a Papua New Guinea Collection of the
Marine Cyanobacterium Lyngbya m ajuscula. J. Nat. Prod. 66, 764–771.
doi: 10.1021/np020492o
Tan, R. X., Jensen, P. R., Williams, P. G., and Fenical, W. (2004). Isolation and
Structure Assignments of Rostratins AD, Cytotoxic Disulfides Produced by the
Marine-Derived Fungus Exserohilum r ostratum. J. Nat. Prod. 67, 1374–1382.
doi: 10.1021/np049920b
Tang, L., Shah, S., Chung, L., Carney, J., Katz, L., Khosla, C., et al. (2000).
Cloning and heterologous expression of the epothilone gene cluster. Science
287, 640–642. doi: 10.1126/science.287.5453.640
Taniguchi, M., Nunnery, J. K., Engene, N., Esquenazi, E., Byrum, T., Dorrestein,
P. C., et al. (2009). Palmyramide A, a Cyclic Depsipeptide from a Palmyra Atoll
Collection of theMarine Cyanobacterium Lyngbyamajuscula†. J. Nat. Prod. 73,
393–398. doi: 10.1021/np900428h
Taori, K., Liu, Y., Paul, V. J., and Luesch, H. (2009). Combinatorial strategies
by marine cyanobacteria: symplostatin 4, an antimitotic natural dolastatin
10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole.
Chembiochem 10, 1634–1639. doi: 10.1002/cbic.200900192
Taori, K., Matthew, S., Rocca, J. R., Paul, V. J., and Luesch, H.
(2007). Lyngbyastatins 5–7, Potent Elastase Inhibitors from Floridian
Marine Cyanobacteria, Lyngbya spp. J. Nat. Prod. 70, 1593–1600.
doi: 10.1021/np0702436
Tareq, F. S., Kim, J. H., Lee, M. A., Lee, H.-S., Lee, Y.-J., Lee, J.
S., et al. (2012). Ieodoglucomides A and B from a marine-derived
bacterium Bacillus licheniformis. Org. Lett. 14, 1464–1467. doi: 10.1021/ol30
0202z
Teruya, T., Sasaki, H., Fukazawa, H., and Suenaga, K. (2009). Bisebromoamide,
a potent cytotoxic peptide from the marine cyanobacterium Lyngbya sp.:
isolation, stereostructure, and biological activity. Org. Lett. 11, 5062–5065.
doi: 10.1021/ol9020546
Thiericke, R., and Rohr, J. (1993). Biological variation of microbial
metabolites by precursor-directed biosynthesis. Nat. Prod. Rep. 10, 265–289.
doi: 10.1039/np9931000265
Thornburg, C. C., Thimmaiah,M., Shaala, L. A., Hau, A.M.,Malmo, J. M., Ishmael,
J. E., et al. (2011). Cyclic depsipeptides, grassypeptolides D and E and Ibu-
epidemethoxylyngbyastatin 3, from a Red Sea Leptolyngbya cyanobacterium. J.
Nat. Prod. 74, 1677–1685. doi: 10.1021/np200270d
Tripathi, A., Puddick, J., Prinsep, M. R., Lee, P. P. F., and Tan, L. T.
(2008). Hantupeptin A, a cytotoxic cyclic depsipeptide from a Singapore
collection of Lyngbya majuscula. J. Nat. Prod. 72, 29–32. doi: 10.1021/np80
0448t
Tripathi, A., Puddick, J., Prinsep, M. R., Lee, P. P. F., and Tan, L. T.
(2010). Hantupeptins B and C, cytotoxic cyclodepsipeptides from the
marine cyanobacterium Lyngbya majuscula. Phytochemistry 71, 307–311.
doi: 10.1016/j.phytochem.2009.10.006
Tripathi, A., Puddick, J., Prinsep, M. R., Rottmann, M., Chan, K. P., Chen, D.
Y.-K., et al. (2011). Lagunamide C, a cytotoxic cyclodepsipeptide from the
marine cyanobacterium Lyngbya majuscula. Phytochemistry 72, 2369–2375.
doi: 10.1016/j.phytochem.2011.08.019
Ugai, T., Minami, A., Gomi, K., and Oikawa, H. (2016). Genome mining approach
for harnessing the cryptic gene cluster in Alternaria solani: production of PKS–
NRPS hybrid metabolite, didymellamide B. Tetrahedr. Lett. 57, 2793–2796.
doi: 10.1016/j.tetlet.2016.05.043
Um, S., Choi, T. J., Kim, H., Kim, B. Y., Kim, S.-H., Lee, S. K., et al. (2013).
Ohmyungsamycins A and B: Cytotoxic and Antimicrobial Cyclic Peptides
Produced by Streptomyces sp. from a Volcanic Island. J. Organic Chem. 78,
12321–12329. doi: 10.1021/jo401974g
Vignesh, S., Raja, A., and James, R. A. (2011). Marine drugs: implication and future
studies. Int. J. Pharmacol. 7, 22–30. doi: 10.3923/ijp.2011.22.30
Vinothkumar, S., and Parameswaran, P. (2013). Recent advances in marine
drug research. Biotechnol. Adv. 31, 1826–1845. doi: 10.1016/j.biotechadv.2013.
02.006
Weist, S., Kittel, C., Bischoff, D., Bister, B., Pfeifer, V., Nicholson, G. J., et al. (2004).
Mutasynthesis of glycopeptide antibiotics: variations of vancomycin’s AB-ring
amino acid 3, 5-dihydroxyphenylglycine. J. Am. Chem. Soc. 126, 5942–5943.
doi: 10.1021/ja0499389
Williams, D. E., Dalisay, D. S., Patrick, B. O., Matainaho, T., Andrusiak, K.,
Deshpande, R., et al. (2011). Padanamides A and B, highly modified linear
tetrapeptides produced in culture by a Streptomyces sp. isolated from a marine
sediment. Organ. Lett. 13, 3936–3939. doi: 10.1021/ol2014494
Williams, P. G., Moore, R. E., and Paul, V. J. (2003a). Isolation and
structure determination of lyngbyastatin 3, a lyngbyastatin 1 homologue
from the marine cyanobacterium lyngbya m ajuscula. Determination of
the configuration of the 4-Amino-2, 2-dimethyl-3-oxopentanoic acid unit
in majusculamide C, dolastatin 12, lyngbyastatin 1, and lyngbyastatin
3 from cyanobacteria. J. Natl. Prod. 66, 1356–1363. doi: 10.1021/np03
02145
Williams, P. G., Yoshida, W. Y., Moore, R. E., and Paul, V. J. (2002a). Isolation and
structure determination of obyanamide, a novel cytotoxic cyclic depsipeptide
from themarine cyanobacterium Lyngbya confervoides. J. Nat. Prod. 65, 29–31.
doi: 10.1021/np0102253
Williams, P. G., Yoshida, W. Y., Moore, R. E., and Paul, V. J. (2002b). Tasiamide,
a cytotoxic peptide from the marine cyanobacterium Symploca sp. J. Nat. Prod.
65, 1336–1339. doi: 10.1021/np020184q
Williams, P. G., Yoshida, W. Y., Moore, R. E., and Paul, V. J. (2003b).
The isolation and structure elucidation of tasiamide B, a 4-amino-
3-hydroxy-5-phenylpentanoic acid containing peptide from the marine
cyanobacterium Symploca sp. J. Nat. Prod. 66, 1006–1009. doi: 10.1021/np03
0114z
Williams, P. G., Yoshida, W. Y., Moore, R. E., and Paul, V. J. (2003c). Tasipeptins A
and B: new cytotoxic depsipeptides from the marine cyanobacterium Symploca
sp. J. Nat. Prod. 66, 620–624. doi: 10.1021/np020582t
Williams, P. G., Yoshida, W. Y., Quon, M. K., Moore, R. E., and Paul, V. J.
(2003d). Ulongapeptin, a cytotoxic cyclic depsipeptide from a Palauan marine
cyanobacterium Lyngbya sp. J. Nat. Prod. 66, 651–654. doi: 10.1021/np03
0050s
Winn, M., Fyans, J., Zhuo, Y., and Micklefield, J. (2016). Recent advances in
engineering nonribosomal peptide assembly lines. Nat. Prod. Rep. 33, 317–347.
doi: 10.1039/C5NP00099H
Wu, X., Bu, X., Wong, K. M., Yan, W., and Guo, Z. (2003). Biomimetic synthesis
of gramicidin S and analogues by enzymatic cyclization of linear precursors on
solid support. Org. Lett. 5, 1749–1752. doi: 10.1021/ol034437y
Wyche, T. P., Hou, Y., Vazquez-Rivera, E., Braun, D., and Bugni, T. S. (2012).
Peptidolipins B–F, Antibacterial Lipopeptides from an Ascidian-Derived
Nocardia sp. J. Nat. Prod. 75, 735–740. doi: 10.1021/np300016r
Yang, L., Tan, R.-X., Wang, Q., Huang, W.-Y., and Yin, Y.-X. (2002). Antifungal
cyclopeptides from Halobacillus litoralis YS3106 of marine origin. Tetrahedron
Lett. 43, 6545–6548. doi: 10.1016/S0040-4039(02)01458-2
Ye, P., Shen, L., Jiang, W., Ye, Y., Chen, C.-T. A., Wu, X., et al. (2014). Zn-Driven
Discovery of a Hydrothermal Vent Fungal Metabolite Clavatustide C, and an
experimental study of the anti-cancer mechanism of clavatustide B.Mar. Drugs
12, 3203–3217. doi: 10.3390/md12063203
Yin, X., Chen, Y., Zhang, L., Wang, Y., and Zabriskie, T. M. (2010).
Enduracidin analogues with altered halogenation patterns produced by
genetically engineered strains of Streptomyces fungicidicus. J. Nat. Prod. 73,
583–589. doi: 10.1021/np900710q
Yu, Z., Lang, G., Kajahn, I., Schmaljohann, R., and Imhoff, J. F. (2008).
Scopularides A and B, cyclodepsipeptides from a marine sponge-
derived fungus, Scopulariopsis brevicaulis. J. Nat. Prod. 71, 1052–1054.
doi: 10.1021/np070580e
Zhang, H. L., Hua, H. M., Pei, Y. H., and Yao, X. S. (2004). Three new
cytotoxic cyclic acylpeptides from marine Bacillus sp. Chem. Pharm. Bullet. 52,
1029–1030. doi: 10.1248/cpb.52.1029
Zheng, J., Xu, Z., Wang, Y., Hong, K., Liu, P., and Zhu, W. (2010). Cyclic
tripeptides from the halotolerant fungusAspergillus sclerotiorum PT06-1. J. Nat.
Prod. 73, 1133–1137. doi: 10.1021/np100198h
Frontiers in Pharmacology | www.frontiersin.org 25 November 2017 | Volume 8 | Article 828
Agrawal et al. Nonribosomal Peptides from Marine Microbes
Zheng, J., Zhu, H., Hong, K., Wang, Y., Liu, P., Wang, X., et al. (2009). Novel cyclic
hexapeptides from marine-derived fungus, Aspergillus sclerotiorum PT06-1.
Org. Lett. 11, 5262–5265. doi: 10.1021/ol902197z
Zhou, L. N., Gao, H. Q., Cai, S. X., Zhu, T. J., Gu, Q. Q., and Li, D. H.
(2011). Two New Cyclic Pentapeptides from the Marine-Derived Fungus
Aspergillus versicolor. Helv. Chim. Acta 94, 1065–1070. doi: 10.1002/hlca.2010
00408
Zhou, X., Huang, H., Chen, Y., Tan, J., Song, Y., Zou, J., et al. (2012).
Marthiapeptide A, an anti-infective and cytotoxic polythiazole
cyclopeptide from a 60 L scale fermentation of the deep sea-derived
Marinactinospora thermotolerans SCSIO 00652. J. Nat. Prod. 75, 2251–2255.
doi: 10.1021/np300554f
Ziemert, N., Podell, S., Penn, K., Badger, J. H., Allen, E., and Jensen, P. R. (2012).
The natural product domain seeker NaPDoS: a phylogeny based bioinformatic
tool to classify secondary metabolite gene diversity. PLoS ONE 7:e34064.
doi: 10.1371/journal.pone.0034064
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Agrawal, Acharya, Adholeya, Barrow and Deshmukh. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 26 November 2017 | Volume 8 | Article 828
